{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:02Z","timestamp":1793228222888,"version":"4.5.0"},"reference-count":526,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030016"],"award-info":[{"award-number":["82030016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230011"],"award-info":[{"award-number":["82230011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82450004"],"award-info":[{"award-number":["82450004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170282"],"award-info":[{"award-number":["82170282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470296"],"award-info":[{"award-number":["82470296"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As immunoregulatory cells, regulatory T cells (Tregs) play pivotal roles in maintaining immune tolerance and preventing autoimmunity. However, Tregs exhibit distinct functions across different diseases. In cancer, Tregs are most likely to suppress antitumor immune responses and promote tumor immune evasion, whereas in inflammatory diseases, functionally competent Tregs mitigate excessive immune activation and facilitate tissue repair. Notably, dysfunctional Tregs lead to persistent inflammation and progression to chronic disease. Therefore, targeting Tregs has emerged as an attractive immunotherapeutic strategy for both cancer and inflammatory disorders. Recent studies have shown that Tregs exhibit instability and plasticity under specific conditions, allowing them to shift between functional and dysfunctional states. A comprehensive understanding of the dynamic changes in Tregs and their regulatory mechanisms in diverse pathological contexts is highly important. In this review, we summarize the dual roles of Tregs in cancer and various inflammatory diseases. We explore the signaling pathways and molecular mechanisms underlying their biological characteristics, with a particular focus on how microenvironmental cues shape Treg behavior. Additionally, we discuss recent advances in Treg-targeted therapies in these disease contexts. Overall, this review greatly advances our understanding of the roles of Tregs in cancer and inflammation and helps inform the development of more precise and effective therapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41392-026-02584-w","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:20:54Z","timestamp":1780309254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Regulatory T cells in cancer and inflammation"],"prefix":"10.1038","volume":"11","author":[{"given":"Haoyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2584_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi, S. et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151\u20131164 (1995).","journal-title":"J. Immunol."},{"key":"2584_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-065X.2011.01018.x","volume":"241","author":"AY Rudensky","year":"2011","unstructured":"Rudensky, A. Y. Regulatory T cells and Foxp3. Immunol. Rev. 241, 260\u2013268 (2011).","journal-title":"Immunol. Rev."},{"key":"2584_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","volume":"22","author":"S Sakaguchi","year":"2004","unstructured":"Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev. Immunol. 22, 531\u2013562 (2004).","journal-title":"Annu Rev. Immunol."},{"key":"2584_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787 (2008).","journal-title":"Cell"},{"key":"2584_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41577-021-00519-w","volume":"21","author":"AR Mu\u00f1oz-Rojas","year":"2021","unstructured":"Mu\u00f1oz-Rojas, A. R. & Mathis, D. Tissue regulatory T cells: regulatory chameleons. Nat. Rev. Immunol. 21, 597\u2013611 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231244","volume":"221","author":"LF Loffredo","year":"2024","unstructured":"Loffredo, L. F., Savage, T. M., Ringham, O. R. & Arpaia, N. Treg-tissue cell interactions in repair and regeneration. J. Exp. Med. 221, e20231244 (2024).","journal-title":"J. Exp. Med."},{"key":"2584_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay, C., Tanaka, A. & Sakaguchi, S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41, 450\u2013465 (2023).","journal-title":"Cancer Cell"},{"key":"2584_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar, M. & Hafler, D. A. Regulatory T cells in autoimmune disease. Nat. Immunol. 19, 665\u2013673 (2018).","journal-title":"Nat. Immunol."},{"key":"2584_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-024-00994-x","volume":"24","author":"TS Sumida","year":"2024","unstructured":"Sumida, T. S., Cheru, N. T. & Hafler, D. A. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nat. Rev. Immunol. 24, 503\u2013517 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin, C., Vo, L. T. & Bluestone, J. A. T(reg) cell-based therapies: challenges and perspectives. Nat. Rev. Immunol. 20, 158\u2013172 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nri3464","volume":"13","author":"S Sakaguchi","year":"2013","unstructured":"Sakaguchi, S. et al. The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13, 461\u2013467 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2015.12.009","volume":"39","author":"AE Overacre","year":"2016","unstructured":"Overacre, A. E. & Vignali, D. A. T(reg) stability: to be or not to be. Curren Opin. Immunol. 39, 39\u201343 (2016).","journal-title":"Curren Opin. Immunol."},{"key":"2584_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","volume":"9","author":"JH Kang","year":"2023","unstructured":"Kang, J. H. & Zappasodi, R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer 9, 911\u2013927 (2023).","journal-title":"Trends Cancer"},{"key":"2584_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2017.76","volume":"18","author":"E Papalexi","year":"2018","unstructured":"Papalexi, E. & Satija, R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat. Rev. Immunol. 18, 35\u201345 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ccell.2022.09.011","volume":"41","author":"WH Hudson","year":"2023","unstructured":"Hudson, W. H. & Wieland, A. Technology meets TILs: deciphering T cell function in the -omics era. Cancer Cell 41, 41\u201357 (2023).","journal-title":"Cancer Cell"},{"key":"2584_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/ni.2554","volume":"14","author":"AK Abbas","year":"2013","unstructured":"Abbas, A. K. et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat. Immunol. 14, 307\u2013308 (2013).","journal-title":"Nat. Immunol."},{"key":"2584_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12160","volume":"259","author":"EM Shevach","year":"2014","unstructured":"Shevach, E. M. & Thornton, A. M. tTregs, pTregs, and iTregs: similarities and differences. Immunol. Rev. 259, 88\u2013102 (2014).","journal-title":"Immunol. Rev."},{"key":"2584_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20120914","volume":"209","author":"JM Weiss","year":"2012","unstructured":"Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J. Exp. Med. 209, 1723\u20131742 (2012).","journal-title":"J. Exp. Med."},{"key":"2584_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1084\/jem.20120822","volume":"209","author":"M Yadav","year":"2012","unstructured":"Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209, 1713\u20131722 (2012).","journal-title":"J. Exp. Med."},{"key":"2584_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.it.2016.08.012","volume":"37","author":"M Kanamori","year":"2016","unstructured":"Kanamori, M. et al. Induced regulatory T cells: their development, stability, and applications. Trends Immunol. 37, 803\u2013811 (2016).","journal-title":"Trends Immunol."},{"key":"2584_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.immuni.2007.11.021","volume":"28","author":"CW Lio","year":"2008","unstructured":"Lio, C. W. & Hsieh, C. S. A two-step process for thymic regulatory T cell development. Immunity 28, 100\u2013111 (2008).","journal-title":"Immunity"},{"key":"2584_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-immunol-100219-020937","volume":"38","author":"PA Savage","year":"2020","unstructured":"Savage, P. A., Klawon, D. E. J. & Miller, C. H. Regulatory T cell development. Annu. Rev. Immunol. 38, 421\u2013453 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"2584_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nature08750","volume":"463","author":"Y Zheng","year":"2010","unstructured":"Zheng, Y. et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463, 808\u2013812 (2010).","journal-title":"Nature"},{"key":"2584_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2014.07.030","volume":"158","author":"X Li","year":"2014","unstructured":"Li, X. et al. Function of a Foxp3 cis-element in protecting regulatory T cell identity. Cell 158, 734\u2013748 (2014).","journal-title":"Cell"},{"key":"2584_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2014.07.031","volume":"158","author":"Y Feng","year":"2014","unstructured":"Feng, Y. et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell 158, 749\u2013763 (2014).","journal-title":"Cell"},{"key":"2584_CR26","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1084\/jem.20070590","volume":"204","author":"JL Coombes","year":"2007","unstructured":"Coombes, J. L. et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757\u20131764 (2007).","journal-title":"J. Exp. Med."},{"key":"2584_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.immuni.2010.09.001","volume":"33","author":"L Xu","year":"2010","unstructured":"Xu, L. et al. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 33, 313\u2013325 (2010).","journal-title":"Immunity"},{"key":"2584_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature12726","volume":"504","author":"N Arpaia","year":"2013","unstructured":"Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451\u2013455 (2013).","journal-title":"Nature"},{"key":"2584_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.313","volume":"50","author":"W Lee","year":"2018","unstructured":"Lee, W. & Lee, G. R. Transcriptional regulation and development of regulatory T cells. Exp. Mol. Med. 50, e456 (2018).","journal-title":"Exp. Mol. Med."},{"key":"2584_CR30","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1073\/pnas.0509484103","volume":"103","author":"MA Gavin","year":"2006","unstructured":"Gavin, M. A. et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103, 6659\u20136664 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899\u2013911 (2009).","journal-title":"Immunity"},{"key":"2584_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271\u2013275 (2008).","journal-title":"Science"},{"key":"2584_CR33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","volume":"55","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi, T. et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity 55, 912\u2013924.e918 (2022).","journal-title":"Immunity"},{"key":"2584_CR34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc, M. et al. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 118, e2023739118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.immuni.2018.07.007","volume":"49","author":"D Bauch\u00e9","year":"2018","unstructured":"Bauch\u00e9, D. et al. LAG3(+) regulatory T cells restrain interleukin-23-producing CX3CR1(+) gut-resident macrophages during Group 3 innate lymphoid cell-driven colitis. Immunity 49, 342\u2013352.e345 (2018).","journal-title":"Immunity"},{"key":"2584_CR36","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.immuni.2025.03.004","volume":"58","author":"M Osaki","year":"2025","unstructured":"Osaki, M. & Sakaguchi, S. Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. Immunity 58, 889\u2013908.e813 (2025).","journal-title":"Immunity"},{"key":"2584_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol. Rev. 276, 121\u2013144 (2017).","journal-title":"Immunol. Rev."},{"key":"2584_CR38","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.celrep.2017.10.090","volume":"21","author":"X Wei","year":"2017","unstructured":"Wei, X. et al. Reciprocal expression of IL-35 and IL-10 defines two distinct effector treg subsets that are required for maintenance of immune tolerance. Cell Rep. 21, 1853\u20131869 (2017).","journal-title":"Cell Rep."},{"key":"2584_CR39","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant, D. V. et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat. Immunol. 20, 724\u2013735 (2019).","journal-title":"Nat. Immunol."},{"key":"2584_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi4613","volume":"7","author":"JM Moreau","year":"2022","unstructured":"Moreau, J. M. et al. Transforming growth factor-\u03b21 in regulatory T cell biology. Sci. Immunol. 7, eabi4613 (2022).","journal-title":"Sci. Immunol."},{"key":"2584_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.immuni.2014.05.019","volume":"41","author":"IS Okoye","year":"2014","unstructured":"Okoye, I. S. et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 41, 89\u2013103 (2014).","journal-title":"Immunity"},{"key":"2584_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/JLB.3MR0420-533RR","volume":"108","author":"C Rojas","year":"2020","unstructured":"Rojas, C. et al. T regulatory cells-derived extracellular vesicles and their contribution to the generation of immune tolerance. J. Leukoc. Biol. 108, 813\u2013824 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"2584_CR43","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.celrep.2019.12.081","volume":"30","author":"JA Sullivan","year":"2020","unstructured":"Sullivan, J. A. et al. Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance. Cell Rep. 30, 1039\u20131051.e1035 (2020).","journal-title":"Cell Rep."},{"key":"2584_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","volume":"8","author":"P Pandiyan","year":"2007","unstructured":"Pandiyan, P. et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8, 1353\u20131362 (2007).","journal-title":"Nat. Immunol."},{"key":"2584_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/intimm\/dxh207","volume":"17","author":"T Barthlott","year":"2005","unstructured":"Barthlott, T. et al. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol. 17, 279\u2013288 (2005).","journal-title":"Int. Immunol."},{"key":"2584_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/mi.2011.62","volume":"5","author":"J Loebbermann","year":"2012","unstructured":"Loebbermann, J. et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol. 5, 161\u2013172 (2012).","journal-title":"Mucosal Immunol."},{"key":"2584_CR47","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao, X. et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635\u2013646 (2007).","journal-title":"Immunity"},{"key":"2584_CR48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41586-020-2040-3","volume":"579","author":"A Vasanthakumar","year":"2020","unstructured":"Vasanthakumar, A. et al. Sex-specific adipose tissue imprinting of regulatory T cells. Nature 579, 581\u2013585 (2020).","journal-title":"Nature"},{"key":"2584_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41590-024-01753-9","volume":"25","author":"SV Torres","year":"2024","unstructured":"Torres, S. V. et al. Two regulatory T cell populations in the visceral adipose tissue shape systemic metabolism. Nat. Immunol. 25, 496\u2013511 (2024).","journal-title":"Nat. Immunol."},{"key":"2584_CR50","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2013.10.054","volume":"155","author":"D Burzyn","year":"2013","unstructured":"Burzyn, D. et al. A special population of regulatory T cells potentiates muscle repair. Cell 155, 1282\u20131295 (2013).","journal-title":"Cell"},{"key":"2584_CR51","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1161\/CIRCULATIONAHA.120.046789","volume":"142","author":"N Xia","year":"2020","unstructured":"Xia, N. et al. A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction. Circulation 142, 1956\u20131973 (2020).","journal-title":"Circulation"},{"key":"2584_CR52","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.immuni.2021.04.022","volume":"54","author":"L Shi","year":"2021","unstructured":"Shi, L. et al. Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke. Immunity 54, 1527\u20131542.e1528 (2021).","journal-title":"Immunity"},{"key":"2584_CR53","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2017.05.002","volume":"169","author":"N Ali","year":"2017","unstructured":"Ali, N. et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell 169, 1119\u20131129.e1111 (2017).","journal-title":"Cell"},{"key":"2584_CR54","doi-asserted-by":"publisher","first-page":"20696","DOI":"10.1073\/pnas.2000372117","volume":"117","author":"H Shime","year":"2020","unstructured":"Shime, H. et al. Proenkephalin(+) regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function. Proc. Natl. Acad. Sci. USA 117, 20696\u201320705 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR55","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000\u20131007 (2009).","journal-title":"Nat. Immunol."},{"key":"2584_CR56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.immuni.2013.08.006","volume":"39","author":"Z Chen","year":"2013","unstructured":"Chen, Z. et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 39, 272\u2013285 (2013).","journal-title":"Immunity"},{"key":"2584_CR57","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.immuni.2010.12.002","volume":"33","author":"YM Kerdiles","year":"2010","unstructured":"Kerdiles, Y. M. et al. Foxo transcription factors control regulatory T cell development and function. Immunity 33, 890\u2013904 (2010).","journal-title":"Immunity"},{"key":"2584_CR58","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/ni1549","volume":"9","author":"Y Tone","year":"2008","unstructured":"Tone, Y. et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9, 194\u2013202 (2008).","journal-title":"Nat. Immunol."},{"key":"2584_CR59","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ni.3540","volume":"17","author":"T Chinen","year":"2016","unstructured":"Chinen, T. et al. An essential role for the IL-2 receptor in T(reg) cell function. Nat. Immunol. 17, 1322\u20131333 (2016).","journal-title":"Nat. Immunol."},{"key":"2584_CR60","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.coi.2010.08.013","volume":"22","author":"Y Xiao","year":"2010","unstructured":"Xiao, Y. et al. Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr. Opin. Immunol. 22, 583\u2013591 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"2584_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo4116","volume":"8","author":"E Montauti","year":"2022","unstructured":"Montauti, E. et al. A deubiquitination module essential for T(reg) fitness in the tumor microenvironment. Sci. Adv. 8, eabo4116 (2022).","journal-title":"Sci. Adv."},{"key":"2584_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.12312","volume":"266","author":"J Barbi","year":"2015","unstructured":"Barbi, J., Pardoll, D. M. & Pan, F. Ubiquitin-dependent regulation of Foxp3 and Treg function. Immunol. Rev. 266, 27\u201345 (2015).","journal-title":"Immunol. Rev."},{"key":"2584_CR63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.immuni.2013.05.018","volume":"39","author":"J van Loosdregt","year":"2013","unstructured":"van Loosdregt, J. et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39, 259\u2013271 (2013).","journal-title":"Immunity"},{"key":"2584_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169365","volume":"133","author":"A Wang","year":"2023","unstructured":"Wang, A. et al. USP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis. J. Clin. Investig. 133, e169365 (2023).","journal-title":"J. Clin. Investig."},{"key":"2584_CR65","doi-asserted-by":"publisher","first-page":"110727","DOI":"10.1016\/j.celrep.2022.110727","volume":"39","author":"V Saxena","year":"2022","unstructured":"Saxena, V. et al. Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses. Cell Rep. 39, 110727 (2022).","journal-title":"Cell Rep."},{"key":"2584_CR66","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41590-024-01746-8","volume":"25","author":"X Long","year":"2024","unstructured":"Long, X. et al. Targeting JMJD1C to selectively disrupt tumor T(reg) cell fitness enhances antitumor immunity. Nat. Immunol. 25, 525\u2013536 (2024).","journal-title":"Nat. Immunol."},{"key":"2584_CR67","doi-asserted-by":"publisher","first-page":"110986","DOI":"10.1016\/j.celrep.2022.110986","volume":"39","author":"J Gu","year":"2022","unstructured":"Gu, J. et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-\u03b2 signaling in regulatory T cells. Cell Rep. 39, 110986 (2022).","journal-title":"Cell Rep."},{"key":"2584_CR68","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi, R. et al. CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours. Nature 591, 652\u2013658 (2021).","journal-title":"Nature"},{"key":"2584_CR69","doi-asserted-by":"publisher","first-page":"113995","DOI":"10.1016\/j.celrep.2024.113995","volume":"43","author":"Z Zou","year":"2024","unstructured":"Zou, Z. et al. ATF4-SLC7A11-GSH axis mediates the acquisition of immunosuppressive properties by activated CD4(+) T cells in low arginine condition. Cell Rep. 43, 113995 (2024).","journal-title":"Cell Rep."},{"key":"2584_CR70","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.immuni.2019.10.001","volume":"51","author":"H Shi","year":"2019","unstructured":"Shi, H. et al. Amino acids license kinase mTORC1 activity and treg cell function via small G proteins Rag and Rheb. Immunity 51, 1012\u20131027.e1017 (2019).","journal-title":"Immunity"},{"key":"2584_CR71","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/ni.3577","volume":"17","author":"VA Gerriets","year":"2016","unstructured":"Gerriets, V. A. et al. Foxp3 and Toll-like receptor signaling balance T(reg) cell anabolic metabolism for suppression. Nat. Immunol. 17, 1459\u20131466 (2016).","journal-title":"Nat. Immunol."},{"key":"2584_CR72","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nature12297","volume":"499","author":"H Zeng","year":"2013","unstructured":"Zeng, H. et al. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 499, 485\u2013490 (2013).","journal-title":"Nature"},{"key":"2584_CR73","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cell.2022.12.030","volume":"186","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Opioid-induced fragile-like regulatory T cells contribute to withdrawal. Cell 186, 591\u2013606.e523 (2023).","journal-title":"Cell"},{"key":"2584_CR74","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","volume":"169","author":"AE Overacre-Delgoffe","year":"2017","unstructured":"Overacre-Delgoffe, A. E. et al. Interferon-\u03b3 drives T(reg) fragility to promote anti-tumor immunity. Cell 169, 1130\u20131141.e1111 (2017).","journal-title":"Cell"},{"key":"2584_CR75","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41577-023-00893-7","volume":"23","author":"JL Trujillo-Ochoa","year":"2023","unstructured":"Trujillo-Ochoa, J. L., Kazemian, M. & Afzali, B. The role of transcription factors in shaping regulatory T cell identity. Nat. Rev. Immunol. 23, 842\u2013856 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR76","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41590-023-01453-w","volume":"24","author":"AM Gocher-Demske","year":"2023","unstructured":"Gocher-Demske, A. M. et al. IFN\u03b3-induction of T(H)1-like regulatory T cells controls antiviral responses. Nat. Immunol. 24, 841\u2013854 (2023).","journal-title":"Nat. Immunol."},{"key":"2584_CR77","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn8608","volume":"386","author":"A Kuratani","year":"2024","unstructured":"Kuratani, A. et al. Platelet factor 4-induced T(H)1-T(reg) polarization suppresses antitumor immunity. Science 386, eadn8608 (2024).","journal-title":"Science"},{"key":"2584_CR78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51, 27\u201341 (2019).","journal-title":"Immunity"},{"key":"2584_CR79","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"2584_CR80","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai, S., Itahashi, K. & Nishikawa, H. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat. Rev. Clin. Oncol. 21, 337\u2013353 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2584_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aao4310","volume":"4","author":"M Ahmadzadeh","year":"2019","unstructured":"Ahmadzadeh, M. et al. Tumor-infiltrating human CD4(+) regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Sci. Immunol. 4, eaao4310 (2019).","journal-title":"Sci. Immunol."},{"key":"2584_CR82","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240445","volume":"222","author":"SN Tan","year":"2025","unstructured":"Tan, S. N. et al. Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39. J. Exp. Med. 222, e20240445 (2025).","journal-title":"J. Exp. Med."},{"key":"2584_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2584_CR84","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito, T. et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679\u2013684 (2016).","journal-title":"Nat. Med."},{"key":"2584_CR85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I. et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2584_CR86","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol. Immunol. 20, 432\u2013447 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"2584_CR87","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257\u2013262 (2020).","journal-title":"Nature"},{"key":"2584_CR88","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200264","volume":"218","author":"GM Gerhard","year":"2021","unstructured":"Gerhard, G. M. et al. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J. Exp. Med. 218, e20200264 (2021).","journal-title":"J. Exp. Med."},{"key":"2584_CR89","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1084\/jem.20050463","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli, F. et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells, inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202, 919\u2013929 (2005).","journal-title":"J. Exp. Med."},{"key":"2584_CR90","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04718-w","volume":"605","author":"F Mair","year":"2022","unstructured":"Mair, F. et al. Extricating human tumour immune alterations from tissue inflammation. Nature 605, 728\u2013735 (2022).","journal-title":"Nature"},{"key":"2584_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21043-4","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat. Commun. 12, 741 (2021).","journal-title":"Nat. Commun."},{"key":"2584_CR92","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792\u2013809.e723 (2021).","journal-title":"Cell"},{"key":"2584_CR93","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","volume":"42","author":"S You","year":"2024","unstructured":"You, S. et al. Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. Cancer Cell 42, 1415\u20131433.e1412 (2024).","journal-title":"Cancer Cell"},{"key":"2584_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49282-1","volume":"15","author":"A Varveri","year":"2024","unstructured":"Varveri, A. et al. Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development. Nat. Commun. 15, 4988 (2024).","journal-title":"Nat. Commun."},{"key":"2584_CR95","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4(+) T cells in melanoma. Nature 605, 532\u2013538 (2022).","journal-title":"Nature"},{"key":"2584_CR96","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2007-05-088831","volume":"110","author":"S Yamazaki","year":"2007","unstructured":"Yamazaki, S. et al. Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood 110, 4293\u20134302 (2007).","journal-title":"Blood"},{"key":"2584_CR97","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf0558","volume":"6","author":"RI Seed","year":"2021","unstructured":"Seed, R. I. et al. A tumor-specific mechanism of T(reg) enrichment mediated by the integrin \u03b1v\u03b28. Sci. Immunol. 6, eabf0558 (2021).","journal-title":"Sci. Immunol."},{"key":"2584_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002787","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J. Immunother. Cancer 9, e002787 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417312","volume":"12","author":"X Meng","year":"2025","unstructured":"Meng, X. et al. Plac1(+) tumor cell-treg interplay supports tumorigenesis and progression of head and neck cancer. Adv. Sci. 12, e2417312 (2025).","journal-title":"Adv. Sci."},{"key":"2584_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37614-6","volume":"14","author":"L Gong","year":"2023","unstructured":"Gong, L. et al. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction. Nat. Commun. 14, 1912 (2023).","journal-title":"Nat. Commun."},{"key":"2584_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02318-6","volume":"24","author":"G Xiao","year":"2025","unstructured":"Xiao, G. et al. Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment. Mol. Cancer 24, 118 (2025).","journal-title":"Mol. Cancer"},{"key":"2584_CR102","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463\u2013479.e410 (2018).","journal-title":"Cancer Cell"},{"key":"2584_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato, L. F. et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat. Commun. 11, 4011 (2020).","journal-title":"Nat. Commun."},{"key":"2584_CR104","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg8817","volume":"9","author":"S Ma","year":"2024","unstructured":"Ma, S. et al. Serine enrichment in tumors promotes regulatory T cell accumulation through sphinganine-mediated regulation of c-Fos. Sci. Immunol. 9, eadg8817 (2024).","journal-title":"Sci. Immunol."},{"key":"2584_CR105","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner, E. N. & Rathmell, J. C. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41, 421\u2013433 (2023).","journal-title":"Cancer Cell"},{"key":"2584_CR106","doi-asserted-by":"publisher","first-page":"ra97","DOI":"10.1126\/scisignal.aab2610","volume":"8","author":"D Klysz","year":"2015","unstructured":"Klysz, D. et al. Glutamine-dependent \u03b1-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci. Signal. 8, ra97 (2015).","journal-title":"Sci. Signal."},{"key":"2584_CR107","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.eururo.2018.09.030","volume":"75","author":"Q Fu","year":"2019","unstructured":"Fu, Q. et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur. Urol. 75, 752\u2013763 (2019).","journal-title":"Eur. Urol."},{"key":"2584_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000764","volume":"8","author":"LA Marshall","year":"2020","unstructured":"Marshall, L. A. et al. Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4. J. Immunother. Cancer 8, e000764 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR109","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1158\/0008-5472.CAN-16-0984","volume":"76","author":"PL Loyher","year":"2016","unstructured":"Loyher, P. L. et al. CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity. Cancer Res. 76, 6483\u20136494 (2016).","journal-title":"Cancer Res."},{"key":"2584_CR110","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","volume":"76","author":"AL Chang","year":"2016","unstructured":"Chang, A. L. et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. 76, 5671\u20135682 (2016).","journal-title":"Cancer Res."},{"key":"2584_CR111","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.it.2025.01.001","volume":"46","author":"Y Wen","year":"2025","unstructured":"Wen, Y. et al. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. Trends Immunol. 46, 153\u2013165 (2025).","journal-title":"Trends Immunol."},{"key":"2584_CR112","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.4049\/jimmunol.0904084","volume":"184","author":"DB Hoelzinger","year":"2010","unstructured":"Hoelzinger, D. B. et al. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J. Immunol. 184, 6833\u20136842 (2010).","journal-title":"J. Immunol."},{"key":"2584_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38578-3","volume":"14","author":"T Tang","year":"2023","unstructured":"Tang, T. et al. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. Nat. Commun. 14, 3364 (2023).","journal-title":"Nat. Commun."},{"key":"2584_CR114","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1158\/0008-5472.CAN-11-2493","volume":"72","author":"LY Chang","year":"2012","unstructured":"Chang, L. Y. et al. Tumor-derived chemokine CCL5 enhances TGF-\u03b2-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 72, 1092\u20131102 (2012).","journal-title":"Cancer Res."},{"key":"2584_CR115","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene, A. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226\u2013230 (2011).","journal-title":"Nature"},{"key":"2584_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2869","volume":"13","author":"M Yan","year":"2011","unstructured":"Yan, M. et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 13, R47 (2011).","journal-title":"Breast Cancer Res."},{"key":"2584_CR117","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","volume":"71","author":"E Righi","year":"2011","unstructured":"Righi, E. et al. CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 71, 5522\u20135534 (2011).","journal-title":"Cancer Res."},{"key":"2584_CR118","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Metabolic instruction of immunity. Cell 169, 570\u2013586 (2017).","journal-title":"Cell"},{"key":"2584_CR119","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 21, 298\u2013308 (2020).","journal-title":"Nat. Immunol."},{"key":"2584_CR120","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson, M. J. et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591, 645\u2013651 (2021).","journal-title":"Nature"},{"key":"2584_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54874-y","volume":"15","author":"W Piao","year":"2024","unstructured":"Piao, W. et al. Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling. Nat. Commun. 15, 10468 (2024).","journal-title":"Nat. Commun."},{"key":"2584_CR122","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","volume":"470","author":"W Tan","year":"2011","unstructured":"Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548\u2013553 (2011).","journal-title":"Nature"},{"key":"2584_CR123","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.immuni.2019.06.017","volume":"51","author":"C Liu","year":"2019","unstructured":"Liu, C. et al. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8(+) T cell-derived interferon-\u03b3. Immunity 51, 381\u2013397.e386 (2019).","journal-title":"Immunity"},{"key":"2584_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26352-2","volume":"12","author":"A Lain\u00e9","year":"2021","unstructured":"Lain\u00e9, A. et al. Regulatory T cells promote cancer immune-escape through integrin \u03b1v\u03b28-mediated TGF-\u03b2 activation. Nat. Commun. 12, 6228 (2021).","journal-title":"Nat. Commun."},{"key":"2584_CR125","doi-asserted-by":"publisher","first-page":"13445","DOI":"10.1073\/pnas.0901944106","volume":"106","author":"DQ Tran","year":"2009","unstructured":"Tran, D. Q. et al. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 106, 13445\u201313450 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR126","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala, M. A. et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity 56, 1613\u20131630.e1615 (2023).","journal-title":"Immunity"},{"key":"2584_CR127","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj, T. et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332\u20131341 (2017).","journal-title":"Nat. Immunol."},{"key":"2584_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add7399","volume":"9","author":"R Sun","year":"2023","unstructured":"Sun, R. et al. Amphiregulin couples IL1RL1(+) regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity. Sci. Adv. 9, eadd7399 (2023).","journal-title":"Sci. Adv."},{"key":"2584_CR129","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 10, 422\u2013439 (2020).","journal-title":"Cancer Discov."},{"key":"2584_CR130","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-023-01504-2","volume":"24","author":"A Glasner","year":"2023","unstructured":"Glasner, A. et al. Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. Nat. Immunol. 24, 1020\u20131035 (2023).","journal-title":"Nat. Immunol."},{"key":"2584_CR131","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1053\/j.gastro.2021.04.041","volume":"161","author":"Y Lu","year":"2021","unstructured":"Lu, Y. et al. Mondoa-thioredoxin-interacting protein axis maintains regulatory T-cell identity and function in colorectal cancer microenvironment. Gastroenterology 161, 575\u2013591.e516 (2021).","journal-title":"Gastroenterology"},{"key":"2584_CR132","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan, F. et al. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer 8, 944\u2013961 (2022).","journal-title":"Trends Cancer"},{"key":"2584_CR133","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/0008-5472.CAN-18-1351","volume":"78","author":"DH Munn","year":"2018","unstructured":"Munn, D. H., Sharma, M. D. & Johnson, T. S. Treg destabilization and reprogramming: implications for cancer immunotherapy. Cancer Res. 78, 5191\u20135199 (2018).","journal-title":"Cancer Res."},{"key":"2584_CR134","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3389\/fimmu.2019.02716","volume":"10","author":"H Shi","year":"2019","unstructured":"Shi, H. & Chi, H. Metabolic control of treg cell stability, plasticity, and tissue-specific heterogeneity. Front. Immunol. 10, 2716 (2019).","journal-title":"Front. Immunol."},{"key":"2584_CR135","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","volume":"187","author":"SM Fendt","year":"2024","unstructured":"Fendt, S. M. 100 years of the Warburg effect: a cancer metabolism endeavor. Cell 187, 3824\u20133828 (2024).","journal-title":"Cell"},{"key":"2584_CR136","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1084\/jem.20151159","volume":"212","author":"MD Buck","year":"2015","unstructured":"Buck, M. D., O\u2019Sullivan, D. & Pearce, E. L. T cell metabolism drives immunity. J. Exp. Med. 212, 1345\u20131360 (2015).","journal-title":"J. Exp. Med."},{"key":"2584_CR137","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","volume":"25","author":"A Angelin","year":"2017","unstructured":"Angelin, A. et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 25, 1282\u20131293.e1287 (2017).","journal-title":"Cell Metab."},{"key":"2584_CR138","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/ni.3077","volume":"16","author":"A Huynh","year":"2015","unstructured":"Huynh, A. et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat. Immunol. 16, 188\u2013196 (2015).","journal-title":"Nat. Immunol."},{"key":"2584_CR139","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/ni.3076","volume":"16","author":"S Shrestha","year":"2015","unstructured":"Shrestha, S. et al. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16, 178\u2013187 (2015).","journal-title":"Nat. Immunol."},{"key":"2584_CR140","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni.3365","volume":"17","author":"J Wei","year":"2016","unstructured":"Wei, J. et al. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat. Immunol. 17, 277\u2013285 (2016).","journal-title":"Nat. Immunol."},{"key":"2584_CR141","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1074-7613(02)00323-0","volume":"16","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769\u2013777 (2002).","journal-title":"Immunity"},{"key":"2584_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis, N. et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6, 6692 (2015).","journal-title":"Nat. Commun."},{"key":"2584_CR143","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89160","volume":"2","author":"D Howie","year":"2017","unstructured":"Howie, D. et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight 2, e89160 (2017).","journal-title":"JCI Insight"},{"key":"2584_CR144","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179572","volume":"135","author":"MA Torres Acosta","year":"2025","unstructured":"Torres Acosta, M. A. et al. AMPK is necessary for Treg functional adaptation to microenvironmental stress during malignancy and viral pneumonia. J. Clin. Investig. 135, e179572 (2025).","journal-title":"J. Clin. Investig."},{"key":"2584_CR145","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nature23665","volume":"548","author":"K Yang","year":"2017","unstructured":"Yang, K. et al. Homeostatic control of metabolic and functional fitness of T(reg) cells by LKB1 signalling. Nature 548, 602\u2013606 (2017).","journal-title":"Nature"},{"key":"2584_CR146","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.immuni.2024.08.008","volume":"57","author":"D Kim","year":"2024","unstructured":"Kim, D. et al. Inhibitory co-receptor Lag3 supports Foxp3(+) regulatory T cell function by restraining Myc-dependent metabolic programming. Immunity 57, 2634\u20132650.e2635 (2024).","journal-title":"Immunity"},{"key":"2584_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42883-2","volume":"14","author":"X Ren","year":"2023","unstructured":"Ren, X. et al. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer. Nat. Commun. 14, 7021 (2023).","journal-title":"Nat. Commun."},{"key":"2584_CR148","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177606","volume":"134","author":"S Verma","year":"2024","unstructured":"Verma, S. et al. Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. J. Clin. Investig. 134, e177606 (2024).","journal-title":"J. Clin. Investig."},{"key":"2584_CR149","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cmet.2018.09.020","volume":"29","author":"L Li","year":"2019","unstructured":"Li, L. et al. TLR8-mediated metabolic control of human treg function: a mechanistic target for cancer immunotherapy. Cell Metab. 29, 103\u2013123.e105 (2019).","journal-title":"Cell Metab."},{"key":"2584_CR150","doi-asserted-by":"publisher","first-page":"E6546","DOI":"10.1073\/pnas.1720113115","volume":"115","author":"I Pacella","year":"2018","unstructured":"Pacella, I. et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc. Natl. Acad. Sci. USA 115, E6546\u2013e6555 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR151","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2017.10.017","volume":"47","author":"M Kishore","year":"2017","unstructured":"Kishore, M. et al. Regulatory T cell migration is dependent on glucokinase-mediated glycolysis. Immunity 47, 875\u2013889.e810 (2017).","journal-title":"Immunity"},{"key":"2584_CR152","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.celrep.2019.03.029","volume":"27","author":"J Miska","year":"2019","unstructured":"Miska, J. et al. HIF-1\u03b1 is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of tregs in glioblastoma. Cell Rep. 27, 226\u2013237.e224 (2019).","journal-title":"Cell Rep."},{"key":"2584_CR153","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.celrep.2019.06.024","volume":"28","author":"Z Fu","year":"2019","unstructured":"Fu, Z. et al. Requirement of mitochondrial transcription factor A in tissue-resident regulatory T cell maintenance and function. Cell Rep. 28, 159\u2013171.e154 (2019).","journal-title":"Cell Rep."},{"key":"2584_CR154","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41586-018-0846-z","volume":"565","author":"SE Weinberg","year":"2019","unstructured":"Weinberg, S. E. et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature 565, 495\u2013499 (2019).","journal-title":"Nature"},{"key":"2584_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05676-6","volume":"9","author":"X Yu","year":"2018","unstructured":"Yu, X. et al. SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation. Nat. Commun. 9, 3157 (2018).","journal-title":"Nat. Commun."},{"key":"2584_CR156","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.03.004","volume":"31","author":"H Kurniawan","year":"2020","unstructured":"Kurniawan, H. et al. Glutathione restricts serine metabolism to preserve regulatory T cell function. Cell Metab. 31, 920\u2013936.e927 (2020).","journal-title":"Cell Metab."},{"key":"2584_CR157","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2020.07.001","volume":"32","author":"T Alissafi","year":"2020","unstructured":"Alissafi, T. et al. Mitochondrial oxidative damage underlies regulatory T cell defects in autoimmunity. Cell Metab. 32, 591\u2013604.e597 (2020).","journal-title":"Cell Metab."},{"key":"2584_CR158","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179874","volume":"135","author":"Z Jiang","year":"2024","unstructured":"Jiang, Z. et al. TMED4 facilitates regulatory T cell suppressive function via ROS homeostasis in tumor and autoimmune mouse models. J. Clin. Investig. 135, e179874 (2024).","journal-title":"J. Clin. Investig."},{"key":"2584_CR159","doi-asserted-by":"publisher","first-page":"189259","DOI":"10.1016\/j.bbcan.2025.189259","volume":"1880","author":"L Yang","year":"2025","unstructured":"Yang, L. et al. Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapy. Biochim. Biophys. Acta Rev. Cancer 1880, 189259 (2025).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2584_CR160","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.celrep.2021.109235","volume":"35","author":"C Xu","year":"2021","unstructured":"Xu, C. et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 35, 109235 (2021).","journal-title":"Cell Rep."},{"key":"2584_CR161","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","volume":"591","author":"SA Lim","year":"2021","unstructured":"Lim, S. A. et al. Lipid signalling enforces functional specialization of T(reg) cells in tumours. Nature 591, 306\u2013311 (2021).","journal-title":"Nature"},{"key":"2584_CR162","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41590-022-01373-1","volume":"24","author":"MJ Kim","year":"2023","unstructured":"Kim, M. J. et al. Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. Nat. Immunol. 24, 148\u2013161 (2023).","journal-title":"Nat. Immunol."},{"key":"2584_CR163","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175897","volume":"134","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Lactate supports Treg function and immune balance via MGAT1 effects on N-glycosylation in the mitochondria. J. Clin. Investig. 134, e175897 (2024).","journal-title":"J. Clin. Investig."},{"key":"2584_CR164","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai, S. et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40, 201\u2013218.e209 (2022).","journal-title":"Cancer Cell"},{"key":"2584_CR165","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.immuni.2024.01.019","volume":"57","author":"R Ding","year":"2024","unstructured":"Ding, R. et al. Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. Immunity 57, 528\u2013540.e526 (2024).","journal-title":"Immunity"},{"key":"2584_CR166","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","volume":"25","author":"BW Labadie","year":"2019","unstructured":"Labadie, B. W., Bao, R. & Luke, J. J. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin. Cancer Res. 25, 1462\u20131471 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR167","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699\u2013708 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2584_CR168","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/0008-5472.CAN-19-1577","volume":"80","author":"Y Long","year":"2020","unstructured":"Long, Y. et al. Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma. Cancer Res. 80, 499\u2013509 (2020).","journal-title":"Cancer Res."},{"key":"2584_CR169","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1084\/jem.20110278","volume":"208","author":"LZ Shi","year":"2011","unstructured":"Shi, L. Z. et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367\u20131376 (2011).","journal-title":"J. Exp. Med."},{"key":"2584_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7353","volume":"6","author":"HW Hsiao","year":"2015","unstructured":"Hsiao, H. W. et al. Deltex1 antagonizes HIF-1\u03b1 and sustains the stability of regulatory T cells in vivo. Nat. Commun. 6, 6353 (2015).","journal-title":"Nat. Commun."},{"key":"2584_CR171","doi-asserted-by":"publisher","first-page":"E2784","DOI":"10.1073\/pnas.1202366109","volume":"109","author":"ET Clambey","year":"2012","unstructured":"Clambey, E. T. et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. USA 109, E2784\u20132793 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18731-y","volume":"11","author":"TS Hsu","year":"2020","unstructured":"Hsu, T. S. et al. HIF-2\u03b1 is indispensable for regulatory T cell function. Nat. Commun. 11, 5005 (2020).","journal-title":"Nat. Commun."},{"key":"2584_CR173","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-020-2246-4","volume":"582","author":"JT Cortez","year":"2020","unstructured":"Cortez, J. T. et al. CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature 582, 416\u2013420 (2020).","journal-title":"Nature"},{"key":"2584_CR174","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.immuni.2014.10.012","volume":"41","author":"JC Vahl","year":"2014","unstructured":"Vahl, J. C. et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool. Immunity 41, 722\u2013736 (2014).","journal-title":"Immunity"},{"key":"2584_CR175","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/ni.3004","volume":"15","author":"AG Levine","year":"2014","unstructured":"Levine, A. G., Arvey, A., Jin, W. & Rudensky, A. Y. Continuous requirement for the TCR in regulatory T cell function. Nat. Immunol. 15, 1070\u20131078 (2014).","journal-title":"Nat. Immunol."},{"key":"2584_CR176","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1515\/hsz-2016-0216","volume":"397","author":"I Meininger","year":"2016","unstructured":"Meininger, I. & Krappmann, D. Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. Biol. Chem. 397, 1315\u20131333 (2016).","journal-title":"Biol. Chem."},{"key":"2584_CR177","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/cdd.2015.104","volume":"24","author":"A Br\u00fcstle","year":"2017","unstructured":"Br\u00fcstle, A. et al. MALT1 is an intrinsic regulator of regulatory T cells. Cell Death Differ. 24, 1214\u20131223 (2017).","journal-title":"Cell Death Differ."},{"key":"2584_CR178","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1215-2","volume":"570","author":"M Di Pilato","year":"2019","unstructured":"Di Pilato, M. et al. Targeting the CBM complex causes T(reg) cells to prime tumours for immune checkpoint therapy. Nature 570, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"2584_CR179","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10203-2","volume":"10","author":"M Rosenbaum","year":"2019","unstructured":"Rosenbaum, M. et al. Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nat. Commun. 10, 2352 (2019).","journal-title":"Nat. Commun."},{"key":"2584_CR180","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472\u2013484 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR181","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","volume":"126","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375\u2013387 (2006).","journal-title":"Cell"},{"key":"2584_CR182","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/ni.2710","volume":"14","author":"K Man","year":"2013","unstructured":"Man, K. et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat. Immunol. 14, 1155\u20131165 (2013).","journal-title":"Nat. Immunol."},{"key":"2584_CR183","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1172\/JCI130426","volume":"130","author":"G Alvisi","year":"2020","unstructured":"Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Investig. 130, 3137\u20133150 (2020).","journal-title":"J. Clin. Investig."},{"key":"2584_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07735-4","volume":"9","author":"SI Koizumi","year":"2018","unstructured":"Koizumi, S. I. et al. JunB regulates homeostasis and suppressive functions of effector regulatory T cells. Nat. Commun. 9, 5344 (2018).","journal-title":"Nat. Commun."},{"key":"2584_CR185","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg1487","volume":"8","author":"AG Dykema","year":"2023","unstructured":"Dykema, A. G. et al. Lung tumor-infiltrating T(reg) have divergent transcriptional profiles and function linked to checkpoint blockade response. Sci. Immunol. 8, eadg1487 (2023).","journal-title":"Sci. Immunol."},{"key":"2584_CR186","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.immuni.2013.10.016","volume":"39","author":"SL Bailey-Bucktrout","year":"2013","unstructured":"Bailey-Bucktrout, S. L. et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39, 949\u2013962 (2013).","journal-title":"Immunity"},{"key":"2584_CR187","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature12428","volume":"501","author":"GM Delgoffe","year":"2013","unstructured":"Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252\u2013256 (2013).","journal-title":"Nature"},{"key":"2584_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44391-9","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. FOXP3(+) regulatory T cell perturbation mediated by the IFN\u03b3-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity. Nat. Commun. 15, 122 (2024).","journal-title":"Nat. Commun."},{"key":"2584_CR189","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41590-019-0555-2","volume":"21","author":"A Hatzioannou","year":"2020","unstructured":"Hatzioannou, A. et al. An intrinsic role of IL-33 in T(reg) cell-mediated tumor immunoevasion. Nat. Immunol. 21, 75\u201385 (2020).","journal-title":"Nat. Immunol."},{"key":"2584_CR190","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41590-024-01755-7","volume":"25","author":"T Wertheimer","year":"2024","unstructured":"Wertheimer, T. et al. IL-23 stabilizes an effector T(reg) cell program in the tumor microenvironment. Nat. Immunol. 25, 512\u2013524 (2024).","journal-title":"Nat. Immunol."},{"key":"2584_CR191","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41568-019-0209-6","volume":"19","author":"Y Shaked","year":"2019","unstructured":"Shaked, Y. The pro-tumorigenic host response to cancer therapies. Nat. Rev. Cancer 19, 667\u2013685 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2584_CR192","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259\u20131271 (2006).","journal-title":"J. Exp. Med."},{"key":"2584_CR193","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin, M. et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 20, 203\u2013217 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2584_CR194","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.trecan.2022.05.005","volume":"8","author":"A Mittal","year":"2022","unstructured":"Mittal, A. et al. Radiotherapy-induced metabolic hallmarks in the tumor microenvironment. Trends Cancer 8, 855\u2013869 (2022).","journal-title":"Trends Cancer"},{"key":"2584_CR195","first-page":"20","volume":"5","author":"JS Wang","year":"2018","unstructured":"Wang, J. S., Wang, H. J. & Qian, H. L. Biological effects of radiation on cancer cells. Mil. Med. Res. 5, 20 (2018).","journal-title":"Mil. Med. Res."},{"key":"2584_CR196","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/2326-6066.CIR-19-0305","volume":"9","author":"M De Martino","year":"2021","unstructured":"De Martino, M. et al. Activin A promotes regulatory T-cell-mediated immunosuppression in irradiated breast cancer. Cancer Immunol. Res. 9, 89\u2013102 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"2584_CR197","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","volume":"5","author":"Y Muroyama","year":"2017","unstructured":"Muroyama, Y. et al. Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment. Cancer Immunol. Res. 5, 992\u20131004 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2584_CR198","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171154","volume":"134","author":"E Frijlink","year":"2024","unstructured":"Frijlink, E. et al. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice. J. Clin. Investig. 134, e171154 (2024).","journal-title":"J. Clin. Investig."},{"key":"2584_CR199","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231717","volume":"222","author":"S Tadepalli","year":"2025","unstructured":"Tadepalli, S. et al. CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy. J. Exp. Med. 222, e20231717 (2025).","journal-title":"J. Exp. Med."},{"key":"2584_CR200","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/ni.3270","volume":"16","author":"JG Price","year":"2015","unstructured":"Price, J. G. et al. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat. Immunol. 16, 1060\u20131068 (2015).","journal-title":"Nat. Immunol."},{"key":"2584_CR201","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1158\/1078-0432.CCR-23-3616","volume":"30","author":"J Bugno","year":"2024","unstructured":"Bugno, J. et al. Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance. Clin. Cancer Res. 30, 4450\u20134463 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR202","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1182\/bloodadvances.2018023119","volume":"2","author":"S Dutt","year":"2018","unstructured":"Dutt, S. et al. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions. Blood Adv. 2, 2568\u20132580 (2018).","journal-title":"Blood Adv."},{"key":"2584_CR203","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/1078-0432.CCR-18-3518","volume":"26","author":"T Savage","year":"2020","unstructured":"Savage, T., Pandey, S. & Guha, C. Postablation modulation after single high-dose radiation therapy improves tumor control via enhanced immunomodulation. Clin. Cancer Res. 26, 910\u2013921 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR204","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/cmi.2010.45","volume":"7","author":"Y Qu","year":"2010","unstructured":"Qu, Y. et al. 2-Gy whole-body irradiation significantly alters the balance of CD4+ CD25- T effector cells and CD4+ CD25+ Foxp3+ T regulatory cells in mice. Cell Mol. Immunol. 7, 419\u2013427 (2010).","journal-title":"Cell Mol. Immunol."},{"key":"2584_CR205","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ijrobp.2010.12.041","volume":"80","author":"F Billiard","year":"2011","unstructured":"Billiard, F., Buard, V., Benderitter, M. & Linard, C. Abdominal \u03b3-radiation induces an accumulation of function-impaired regulatory T cells in the small intestine. Int. J. Radiat. Oncol. Biol. Phys. 80, 869\u2013876 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2584_CR206","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12865-020-00349-w","volume":"21","author":"SS Beauford","year":"2020","unstructured":"Beauford, S. S., Kumari, A. & Garnett-Benson, C. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells. BMC Immunol. 21, 18 (2020).","journal-title":"BMC Immunol."},{"key":"2584_CR207","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"2584_CR208","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","volume":"41","author":"M Piper","year":"2023","unstructured":"Piper, M. et al. Simultaneous targeting of PD-1 and IL-2R\u03b2\u03b3 with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell 41, 950\u2013969.e956 (2023).","journal-title":"Cancer Cell"},{"key":"2584_CR209","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000826","volume":"8","author":"D Ji","year":"2020","unstructured":"Ji, D. et al. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. J. Immunother. Cancer 8, e000826 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR210","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0305-7372(03)00116-6","volume":"29","author":"E Espinosa","year":"2003","unstructured":"Espinosa, E., Zamora, P., Feliu, J. & Gonz\u00e1lez Bar\u00f3n, M. Classification of anticancer drugs-a new system based on therapeutic targets. Cancer Treat. Rev. 29, 515\u2013523 (2003).","journal-title":"Cancer Treat. Rev."},{"key":"2584_CR211","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/eji.200324181","volume":"34","author":"F Ghiringhelli","year":"2004","unstructured":"Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide, which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336\u2013344 (2004).","journal-title":"Eur. J. Immunol."},{"key":"2584_CR212","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","volume":"45","author":"R Daill\u00e8re","year":"2016","unstructured":"Daill\u00e8re, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931\u2013943 (2016).","journal-title":"Immunity"},{"key":"2584_CR213","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","volume":"72","author":"DT Le","year":"2012","unstructured":"Le, D. T. & Jaffee, E. M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 72, 3439\u20133444 (2012).","journal-title":"Cancer Res."},{"key":"2584_CR214","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-17-3102","volume":"78","author":"S Hibino","year":"2018","unstructured":"Hibino, S. et al. Inhibition of Nr4a receptors enhances antitumor immunity by breaking treg-mediated immune tolerance. Cancer Res. 78, 3027\u20133040 (2018).","journal-title":"Cancer Res."},{"key":"2584_CR215","first-page":"20143","volume":"16","author":"Y Wen","year":"2024","unstructured":"Wen, Y. et al. Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced cancer ferroptosis through the accumulation of ROS. ACS Appl. Mater. Interfaces 16, 20143\u201320156 (2024).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2584_CR216","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1037-z","volume":"14","author":"E Eriksson","year":"2016","unstructured":"Eriksson, E. et al. Gemcitabine reduces MDSCs, tregs and TGF\u03b2-1 while restoring the Teff\/Treg ratio in patients with pancreatic cancer. J. Transl. Med. 14, 282 (2016).","journal-title":"J. Transl. Med."},{"key":"2584_CR217","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ccell.2023.04.003","volume":"41","author":"A Obradovic","year":"2023","unstructured":"Obradovic, A. et al. Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators. Cancer Cell 41, 933\u2013949.e911 (2023).","journal-title":"Cancer Cell"},{"key":"2584_CR218","first-page":"61","volume":"25","author":"B Guo","year":"2023","unstructured":"Guo, B. et al. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative \u201ccold\u201d triple-negative breast cancer. Bioact. Mater. 25, 61\u201372 (2023).","journal-title":"Bioact. Mater."},{"key":"2584_CR219","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ccell.2025.02.017","volume":"43","author":"S Lamorte","year":"2025","unstructured":"Lamorte, S. et al. Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. Cancer Cell 43, 955\u2013969.e910 (2025).","journal-title":"Cancer Cell"},{"key":"2584_CR220","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","volume":"86","author":"X Cheng","year":"2022","unstructured":"Cheng, X. et al. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol. 86, 408\u2013419 (2022).","journal-title":"Semin Cancer Biol."},{"key":"2584_CR221","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos, O., Lawson, C., Rouleau, S. & Tai, L. H. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J. Immunother. Cancer 6, 86 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR222","doi-asserted-by":"publisher","first-page":"E415","DOI":"10.1073\/pnas.1211850110","volume":"110","author":"J Predina","year":"2013","unstructured":"Predina, J. et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc. Natl. Acad. Sci. USA 110, E415\u2013424 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR223","doi-asserted-by":"publisher","first-page":"994319","DOI":"10.3389\/fimmu.2022.994319","volume":"13","author":"M Patysheva","year":"2022","unstructured":"Patysheva, M. et al. Monocyte programming by cancer therapy. Front. Immunol. 13, 994319 (2022).","journal-title":"Front. Immunol."},{"key":"2584_CR224","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.4049\/jimmunol.1501677","volume":"196","author":"L Zhou","year":"2016","unstructured":"Zhou, L. et al. Propranolol attenuates surgical stress-induced elevation of the regulatory T cell response in patients undergoing radical mastectomy. J. Immunol. 196, 3460\u20133469 (2016).","journal-title":"J. Immunol."},{"key":"2584_CR225","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","volume":"21","author":"DT Weed","year":"2015","unstructured":"Weed, D. T. et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21, 39\u201348 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR226","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.xcrm.2024.101615","volume":"5","author":"C Zhang","year":"2024","unstructured":"Zhang, C. et al. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE\/CTONG2104). Cell Rep. Med. 5, 101615 (2024).","journal-title":"Cell Rep. Med."},{"key":"2584_CR227","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010634","volume":"13","author":"K Jinushi","year":"2025","unstructured":"Jinushi, K. et al. Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors. J. Immunother. Cancer 13, e010634 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR228","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"2584_CR229","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L. et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16, 101 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2584_CR230","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller, N., Anderson, A. C. & Kuchroo, V. K. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity 57, 206\u2013222 (2024).","journal-title":"Immunity"},{"key":"2584_CR231","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.immuni.2013.11.017","volume":"40","author":"T Honda","year":"2014","unstructured":"Honda, T. et al. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 40, 235\u2013247 (2014).","journal-title":"Immunity"},{"key":"2584_CR232","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka, T. et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209, 1201\u20131217 (2012).","journal-title":"J. Exp. Med."},{"key":"2584_CR233","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2584_CR234","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada, T. et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA 116, 9999\u201310008 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR235","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","volume":"42","author":"SN Geels","year":"2024","unstructured":"Geels, S. N. et al. Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell 42, 1051\u20131066.e1057 (2024).","journal-title":"Cancer Cell"},{"key":"2584_CR236","doi-asserted-by":"publisher","first-page":"152391","DOI":"10.1016\/j.imbio.2023.152391","volume":"228","author":"J Lao","year":"2023","unstructured":"Lao, J. et al. Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer. Immunobiology 228, 152391 (2023).","journal-title":"Immunobiology"},{"key":"2584_CR237","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk, M. et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci. Immunol. 8, eabn6173 (2023).","journal-title":"Sci. Immunol."},{"key":"2584_CR238","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346\u20131358 (2020).","journal-title":"Nat. Immunol."},{"key":"2584_CR239","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081\u20133096.e3019 (2025).","journal-title":"Cell"},{"key":"2584_CR240","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/gutjnl-2023-330024","volume":"73","author":"BL Green","year":"2024","unstructured":"Green, B. L. et al. Immunosuppressive CD29(+) Treg accumulation in the liver in mice on checkpoint inhibitor therapy. Gut 73, 509\u2013520 (2024).","journal-title":"Gut"},{"key":"2584_CR241","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41590-025-02172-0","volume":"26","author":"JX Lim","year":"2025","unstructured":"Lim, J. X. et al. PD-1 receptor deficiency enhances CD30(+) T(reg) cell function in melanoma. Nat. Immunol. 26, 1074\u20131086 (2025).","journal-title":"Nat. Immunol."},{"key":"2584_CR242","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009435","volume":"13","author":"M Attias","year":"2025","unstructured":"Attias, M. et al. Anti-PD-1 amplifies costimulation in melanoma-infiltrating T(h)1-like Foxp3(+) regulatory T cells to alleviate local immunosuppression. J. Immunother. Cancer 13, e009435 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR243","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.immuni.2018.05.006","volume":"49","author":"C Stathopoulou","year":"2018","unstructured":"Stathopoulou, C. et al. PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains foxp3 transcription factor stability in induced regulatory T cells. Immunity 49, 247\u2013263.e247 (2018).","journal-title":"Immunity"},{"key":"2584_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29930-0","volume":"13","author":"W Piao","year":"2022","unstructured":"Piao, W. et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nat. Commun. 13, 2176 (2022).","journal-title":"Nat. Commun."},{"key":"2584_CR245","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.it.2018.10.009","volume":"39","author":"Y Liu","year":"2018","unstructured":"Liu, Y. & Zheng, P. How does an anti-CTLA-4 antibody promote cancer immunity? Trends Immunol. 39, 953\u2013956 (2018).","journal-title":"Trends Immunol."},{"key":"2584_CR246","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"F Arce Vargas","year":"2018","unstructured":"Arce Vargas, F. et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33, 649\u2013663.e644 (2018).","journal-title":"Cancer Cell"},{"key":"2584_CR247","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41422-018-0011-0","volume":"28","author":"X Du","year":"2018","unstructured":"Du, X. et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 28, 416\u2013432 (2018).","journal-title":"Cell Res."},{"key":"2584_CR248","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25, 1233\u20131238 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR249","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","volume":"112","author":"B Kavanagh","year":"2008","unstructured":"Kavanagh, B. et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112, 1175\u20131183 (2008).","journal-title":"Blood"},{"key":"2584_CR250","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni, F. et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell 184, 3998\u20134015.e3919 (2021).","journal-title":"Cell"},{"key":"2584_CR251","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007785","volume":"11","author":"KA Jenkins","year":"2023","unstructured":"Jenkins, K. A. et al. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. J. Immunother. Cancer 11, e007785 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR252","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock, A. J. et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat. Med. 30, 2558\u20132567 (2024).","journal-title":"Nat. Med."},{"key":"2584_CR253","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2404661121","volume":"121","author":"S Mok","year":"2024","unstructured":"Mok, S. et al. Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy. Proc. Natl. Acad. Sci. USA 121, e2404661121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR254","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"2584_CR255","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy, C. et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat. Immunol. 23, 757\u2013767 (2022).","journal-title":"Nat. Immunol."},{"key":"2584_CR256","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk3702","volume":"17","author":"AS Rolig","year":"2025","unstructured":"Rolig, A. S. et al. The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming. Sci. Transl. Med. 17, eadk3702 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR257","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164809","volume":"133","author":"J Huuhtanen","year":"2023","unstructured":"Huuhtanen, J. et al. Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma. J. Clin. Investig. 133, e164809 (2023).","journal-title":"J. Clin. Investig."},{"key":"2584_CR258","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173\u2013185 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR259","doi-asserted-by":"publisher","first-page":"109699","DOI":"10.1016\/j.celrep.2021.109699","volume":"36","author":"H Banerjee","year":"2021","unstructured":"Banerjee, H. et al. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 36, 109699 (2021).","journal-title":"Cell Rep."},{"key":"2584_CR260","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"KO Dixon","year":"2021","unstructured":"Dixon, K. O. et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature 595, 101\u2013106 (2021).","journal-title":"Nature"},{"key":"2584_CR261","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-018-0713-7","volume":"37","author":"JF Liu","year":"2018","unstructured":"Liu, J. F. et al. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J. Exp. Clin. Cancer Res. 37, 44 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2584_CR262","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.3389\/fimmu.2019.02936","volume":"10","author":"SM Toor","year":"2019","unstructured":"Toor, S. M. et al. Immune checkpoints in circulating and tumor-infiltrating CD4(+) T cell subsets in colorectal cancer patients. Front. Immunol. 10, 2936 (2019).","journal-title":"Front. Immunol."},{"key":"2584_CR263","doi-asserted-by":"publisher","first-page":"107662","DOI":"10.1016\/j.intimp.2021.107662","volume":"96","author":"W Zhong","year":"2021","unstructured":"Zhong, W. et al. High levels of Tim-3(+)Foxp3(+)Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients. Int. Immunopharmacol. 96, 107662 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"2584_CR264","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48\u201357 (2009).","journal-title":"Nat. Immunol."},{"key":"2584_CR265","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","volume":"20","author":"S Liu","year":"2013","unstructured":"Liu, S. et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 20, 456\u2013464 (2013).","journal-title":"Cell Death Differ."},{"key":"2584_CR266","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1182\/blood-2013-02-481788","volume":"122","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells. Blood 122, 2823\u20132836 (2013).","journal-title":"Blood"},{"key":"2584_CR267","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller, N. et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40, 569\u2013581 (2014).","journal-title":"Immunity"},{"key":"2584_CR268","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121157","volume":"3","author":"J Fourcade","year":"2018","unstructured":"Fourcade, J. et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight 3, e121157 (2018).","journal-title":"JCI Insight"},{"key":"2584_CR269","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan, X. et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature 627, 646\u2013655 (2024).","journal-title":"Nature"},{"key":"2584_CR270","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1002\/cam4.2976","volume":"9","author":"F Chen","year":"2020","unstructured":"Chen, F., Xu, Y., Chen, Y. & Shan, S. TIGIT enhances CD4(+) regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model. Cancer Med. 9, 3584\u20133591 (2020).","journal-title":"Cancer Med."},{"key":"2584_CR271","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","volume":"7","author":"L Wu","year":"2019","unstructured":"Wu, L. et al. Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol. Res. 7, 1700\u20131713 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2584_CR272","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR273","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1084\/jem.20080099","volume":"205","author":"SA Quezada","year":"2008","unstructured":"Quezada, S. A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125\u20132138 (2008).","journal-title":"J. Exp. Med."},{"key":"2584_CR274","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-016-0140-2","volume":"4","author":"JJ Luke","year":"2016","unstructured":"Luke, J. J., Zha, Y., Matijevich, K. & Gajewski, T. F. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. J. Immunother. Cancer 4, 35 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR275","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","volume":"46","author":"F Arce Vargas","year":"2017","unstructured":"Arce Vargas, F. et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577\u2013586 (2017).","journal-title":"Immunity"},{"key":"2584_CR276","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon, I. et al. CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat. cancer 1, 1153\u20131166 (2020).","journal-title":"Nat. cancer"},{"key":"2584_CR277","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ni759","volume":"3","author":"J Shimizu","year":"2002","unstructured":"Shimizu, J. et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135\u2013142 (2002).","journal-title":"Nat. Immunol."},{"key":"2584_CR278","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22885-8","volume":"12","author":"Z Amoozgar","year":"2021","unstructured":"Amoozgar, Z. et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat. Commun. 12, 2582 (2021).","journal-title":"Nat. Commun."},{"key":"2584_CR279","doi-asserted-by":"publisher","first-page":"588682","DOI":"10.3389\/fimmu.2020.588682","volume":"11","author":"J Tian","year":"2020","unstructured":"Tian, J., Zhang, B., Rui, K. & Wang, S. The role of GITR\/GITRL interaction in autoimmune diseases. Front. Immunol. 11, 588682 (2020).","journal-title":"Front. Immunol."},{"key":"2584_CR280","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-16-2000","volume":"23","author":"R Leyland","year":"2017","unstructured":"Leyland, R. et al. A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy that is further enhanced in combination with an OX40 agonist. Clin. Cancer Res. 23, 3416\u20133427 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR281","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1084\/jem.20050940","volume":"202","author":"K Ko","year":"2005","unstructured":"Ko, K. et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 202, 885\u2013891 (2005).","journal-title":"J. Exp. Med."},{"key":"2584_CR282","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","volume":"25","author":"R Zappasodi","year":"2019","unstructured":"Zappasodi, R. et al. Rational design of anti-GITR-based combination immunotherapy. Nat. Med. 25, 759\u2013766 (2019).","journal-title":"Nat. Med."},{"key":"2584_CR283","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s43018-022-00334-9","volume":"3","author":"S Chan","year":"2022","unstructured":"Chan, S. et al. An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy. Nat. Cancer 3, 337\u2013354 (2022).","journal-title":"Nat. Cancer"},{"key":"2584_CR284","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1172\/JCI128672","volume":"130","author":"ZT Freeman","year":"2020","unstructured":"Freeman, Z. T. et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. J. Clin. Investig. 130, 1405\u20131416 (2020).","journal-title":"J. Clin. Investig."},{"key":"2584_CR285","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"2584_CR286","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.immuni.2018.09.014","volume":"49","author":"SL Buchan","year":"2018","unstructured":"Buchan, S. L. et al. Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity 49, 958\u2013970.e957 (2018).","journal-title":"Immunity"},{"key":"2584_CR287","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1084\/jem.20121190","volume":"210","author":"MA Curran","year":"2013","unstructured":"Curran, M. A. et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J. Exp. Med. 210, 743\u2013755 (2013).","journal-title":"J. Exp. Med."},{"key":"2584_CR288","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","volume":"56","author":"R Singh","year":"2024","unstructured":"Singh, R. et al. 4-1BB immunotherapy: advances and hurdles. Exp. Mol. Med. 56, 32\u201339 (2024).","journal-title":"Exp. Mol. Med."},{"key":"2584_CR289","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10088-1","volume":"10","author":"X Qi","year":"2019","unstructured":"Qi, X. et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc\u03b3R affinity. Nat. Commun. 10, 2141 (2019).","journal-title":"Nat. Commun."},{"key":"2584_CR290","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41551-024-01303-6","volume":"9","author":"Y Cai","year":"2025","unstructured":"Cai, Y. et al. Concurrent intratumoural T(reg) cell depletion and CD8(+) T cell expansion via a cleavable anti-4-1BB-interleukin-15 fusion protein. Nat. Biomed. Eng. 9, 952\u2013966 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"2584_CR291","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942\u2013949 (2004).","journal-title":"Nat. Med."},{"key":"2584_CR292","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1158\/0008-5472.CAN-11-0573","volume":"71","author":"J Faget","year":"2011","unstructured":"Faget, J. et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res. 71, 6143\u20136152 (2011).","journal-title":"Cancer Res."},{"key":"2584_CR293","doi-asserted-by":"publisher","first-page":"17945","DOI":"10.1073\/pnas.1316796110","volume":"110","author":"D Sugiyama","year":"2013","unstructured":"Sugiyama, D. et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. USA 110, 17945\u201317950 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR294","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1073\/pnas.1621280114","volume":"114","author":"Y Barsheshet","year":"2017","unstructured":"Barsheshet, Y. et al. CCR8(+)FOXp3(+) T(reg) cells as master drivers of immune regulation. Proc. Natl. Acad. Sci. USA 114, 6086\u20136091 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR295","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00262-020-02583-y","volume":"69","author":"T Wang","year":"2020","unstructured":"Wang, T. et al. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. Cancer Immunol. Immunother. 69, 1855\u20131867 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"2584_CR296","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13046-025-03286-x","volume":"44","author":"B Tian","year":"2025","unstructured":"Tian, B. et al. CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype. J. Exp. Clin. Cancer Res. 44, 113 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2584_CR297","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1535-7163.MCT-22-0570","volume":"22","author":"Y Nagira","year":"2023","unstructured":"Nagira, Y. et al. S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. Mol. Cancer Ther. 22, 1063\u20131072 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"2584_CR298","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","volume":"25","author":"T Doi","year":"2019","unstructured":"Doi, T. et al. A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors. Clin. Cancer Res. 25, 6614\u20136622 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR299","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","volume":"187","author":"Y Luo","year":"2024","unstructured":"Luo, Y. et al. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell 187, 4905\u20134925.e4924 (2024).","journal-title":"Cell"},{"key":"2584_CR300","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida, T. et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br. J. Haematol. 169, 672\u2013682 (2015).","journal-title":"Br. J. Haematol."},{"key":"2584_CR301","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02696-6","volume":"9","author":"R Ravi","year":"2018","unstructured":"Ravi, R. et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy. Nat. Commun. 9, 741 (2018).","journal-title":"Nat. Commun."},{"key":"2584_CR302","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"2584_CR303","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","volume":"22","author":"DVF Tauriello","year":"2022","unstructured":"Tauriello, D. V. F., Sancho, E. & Batlle, E. Overcoming TGF\u03b2-mediated immune evasion in cancer. Nat. Rev. Cancer 22, 25\u201344 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2584_CR304","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni, M. A. & Naing, A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9, 716\u2013725 (2023).","journal-title":"Trends Cancer"},{"key":"2584_CR305","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.immuni.2008.02.017","volume":"28","author":"YP Rubtsov","year":"2008","unstructured":"Rubtsov, Y. P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28, 546\u2013558 (2008).","journal-title":"Immunity"},{"key":"2584_CR306","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2011.03.018","volume":"34","author":"A Chaudhry","year":"2011","unstructured":"Chaudhry, A. et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34, 566\u2013578 (2011).","journal-title":"Immunity"},{"key":"2584_CR307","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.immuni.2016.01.013","volume":"44","author":"ME Turnis","year":"2016","unstructured":"Turnis, M. E. et al. Interleukin-35 limits anti-tumor immunity. Immunity 44, 316\u2013329 (2016).","journal-title":"Immunity"},{"key":"2584_CR308","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","volume":"28","author":"EA Lim","year":"2022","unstructured":"Lim, E. A. et al. Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors. Clin. Cancer Res. 28, 4871\u20134884 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2584_CR309","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/2326-6066.CIR-19-0143","volume":"8","author":"K Jung","year":"2020","unstructured":"Jung, K. et al. A neuropilin-1 antagonist exerts antitumor immunity by inhibiting the suppressive function of intratumoral regulatory T cells. Cancer Immunol. Res. 8, 46\u201356 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2584_CR310","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami, S. et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Investig. 128, 3813\u20133818 (2018).","journal-title":"J. Clin. Investig."},{"key":"2584_CR311","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 23, 3262\u20133274 (2018).","journal-title":"Cell Rep."},{"key":"2584_CR312","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s44321-025-00200-y","volume":"17","author":"Q Zhou","year":"2025","unstructured":"Zhou, Q. et al. Lanatoside C activates the E3 ligase STUB1 to inhibit FOXP3 transcriptional activity and promote antitumor immunity. EMBO Mol. Med. 17, 563\u2013588 (2025).","journal-title":"EMBO Mol. Med."},{"key":"2584_CR313","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ebiom.2016.10.018","volume":"13","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Ubiquitin-specific protease-7 inhibition impairs tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity. EBioMedicine 13, 99\u2013112 (2016).","journal-title":"EBioMedicine"},{"key":"2584_CR314","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature07201","volume":"454","author":"R Medzhitov","year":"2008","unstructured":"Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428\u2013435 (2008).","journal-title":"Nature"},{"key":"2584_CR315","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/ni1276","volume":"6","author":"CN Serhan","year":"2005","unstructured":"Serhan, C. N. & Savill, J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191\u20131197 (2005).","journal-title":"Nat. Immunol."},{"key":"2584_CR316","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2010.03.006","volume":"140","author":"R Medzhitov","year":"2010","unstructured":"Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell 140, 771\u2013776 (2010).","journal-title":"Cell"},{"key":"2584_CR317","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk3248","volume":"387","author":"DEJ Klawon","year":"2025","unstructured":"Klawon, D. E. J. et al. Regulatory T cells constrain T cells of shared specificity to enforce tolerance during infection. Science 387, eadk3248 (2025).","journal-title":"Science"},{"key":"2584_CR318","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Multiple sclerosis. Lancet 391, 1622\u20131636 (2018).","journal-title":"Lancet"},{"key":"2584_CR319","doi-asserted-by":"publisher","first-page":"996469","DOI":"10.3389\/fimmu.2022.996469","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu, R. et al. Autoreactive lymphocytes in multiple sclerosis: pathogenesis and treatment target. Front. Immunol. 13, 996469 (2022).","journal-title":"Front. Immunol."},{"key":"2584_CR320","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1084\/jem.20031579","volume":"199","author":"V Viglietta","year":"2004","unstructured":"Viglietta, V., Baecher-Allan, C., Weiner, H. L. & Hafler, D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971\u2013979 (2004).","journal-title":"J. Exp. Med."},{"key":"2584_CR321","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nm.2389","volume":"17","author":"M Dominguez-Villar","year":"2011","unstructured":"Dominguez-Villar, M., Baecher-Allan, C. M. & Hafler, D. A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 17, 673\u2013675 (2011).","journal-title":"Nat. Med."},{"key":"2584_CR322","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.msard.2015.11.004","volume":"5","author":"A Noori-Zadeh","year":"2016","unstructured":"Noori-Zadeh, A. et al. Regulatory T cell number in multiple sclerosis patients: a meta-analysis. Mult. Scler. Relat. Disord. 5, 73\u201376 (2016).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"2584_CR323","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41590-018-0236-6","volume":"19","author":"T Sumida","year":"2018","unstructured":"Sumida, T. et al. Activated \u03b2-catenin in Foxp3(+) regulatory T cells links inflammatory environments to autoimmunity. Nat. Immunol. 19, 1391\u20131402 (2018).","journal-title":"Nat. Immunol."},{"key":"2584_CR324","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1172\/JCI81151","volume":"125","author":"AL Hernandez","year":"2015","unstructured":"Hernandez, A. L. et al. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J. Clin. Investig. 125, 4212\u20134222 (2015).","journal-title":"J. Clin. Investig."},{"key":"2584_CR325","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature11868","volume":"496","author":"M Kleinewietfeld","year":"2013","unstructured":"Kleinewietfeld, M. et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496, 518\u2013522 (2013).","journal-title":"Nature"},{"key":"2584_CR326","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41423-023-01011-2","volume":"20","author":"E Grajchen","year":"2023","unstructured":"Grajchen, E. et al. Fatty acid desaturation by stearoyl-CoA desaturase-1 controls regulatory T cell differentiation and autoimmunity. Cell Mol. Immunol. 20, 666\u2013679 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"2584_CR327","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","volume":"581","author":"C Campbell","year":"2020","unstructured":"Campbell, C. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581, 475\u2013479 (2020).","journal-title":"Nature"},{"key":"2584_CR328","doi-asserted-by":"publisher","first-page":"102028","DOI":"10.1016\/j.xcrm.2025.102028","volume":"6","author":"M Antonini Cencicchio","year":"2025","unstructured":"Antonini Cencicchio, M. et al. Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity. Cell Rep. Med. 6, 102028 (2025).","journal-title":"Cell Rep. Med."},{"key":"2584_CR329","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.cell.2020.02.035","volume":"180","author":"A Duscha","year":"2020","unstructured":"Duscha, A. et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell 180, 1067\u20131080.e1016 (2020).","journal-title":"Cell"},{"key":"2584_CR330","doi-asserted-by":"publisher","first-page":"103240","DOI":"10.1016\/j.redox.2024.103240","volume":"75","author":"M Wu","year":"2024","unstructured":"Wu, M. et al. Peroxynitrite reduces Treg cell expansion and function by mediating IL-2R nitration and aggravates multiple sclerosis pathogenesis. Redox Biol. 75, 103240 (2024).","journal-title":"Redox Biol."},{"key":"2584_CR331","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167457","volume":"9","author":"P Baeten","year":"2024","unstructured":"Baeten, P. et al. Rapamycin rescues loss of function in blood-brain barrier-interacting Tregs. JCI Insight 9, e167457 (2024).","journal-title":"JCI Insight"},{"key":"2584_CR332","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155693","volume":"132","author":"M Fujiwara","year":"2022","unstructured":"Fujiwara, M. et al. microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance. J. Clin. Investig. 132, e155693 (2022).","journal-title":"J. Clin. Investig."},{"key":"2584_CR333","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","volume":"518","author":"KK Farh","year":"2015","unstructured":"Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337\u2013343 (2015).","journal-title":"Nature"},{"key":"2584_CR334","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp1720","volume":"16","author":"TS Sumida","year":"2024","unstructured":"Sumida, T. S. et al. An autoimmune transcriptional circuit drives FOXP3(+) regulatory T cell dysfunction. Sci. Transl. Med. 16, eadp1720 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR335","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720\u2013727 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2584_CR336","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart, D. C. & Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627\u20131640 (2007).","journal-title":"Lancet"},{"key":"2584_CR337","doi-asserted-by":"publisher","first-page":"107184","DOI":"10.1016\/j.phrs.2024.107184","volume":"203","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. Metabolic regulation of the Th17\/Treg balance in inflammatory bowel disease. Pharm. Res. 203, 107184 (2024).","journal-title":"Pharm. Res."},{"key":"2584_CR338","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41590-024-02075-6","volume":"26","author":"S Dikiy","year":"2025","unstructured":"Dikiy, S. et al. Terminal differentiation and persistence of effector regulatory T cells essential for preventing intestinal inflammation. Nat. Immunol. 26, 444\u2013458 (2025).","journal-title":"Nat. Immunol."},{"key":"2584_CR339","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41590-023-01667-y","volume":"24","author":"CH Lin","year":"2023","unstructured":"Lin, C. H. et al. Selective IL-27 production by intestinal regulatory T cells permits gut-specific regulation of T(H)17 cell immunity. Nat. Immunol. 24, 2108\u20132120 (2023).","journal-title":"Nat. Immunol."},{"key":"2584_CR340","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1053\/j.gastro.2024.01.007","volume":"166","author":"RL Kosinsky","year":"2024","unstructured":"Kosinsky, R. L. et al. The FOXP3(+) pro-inflammatory T cell: a potential therapeutic target in Crohn\u2019s disease. Gastroenterology 166, 631\u2013644.e617 (2024).","journal-title":"Gastroenterology"},{"key":"2584_CR341","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1053\/j.gastro.2010.12.002","volume":"140","author":"Z Hovhannisyan","year":"2011","unstructured":"Hovhannisyan, Z., Treatman, J., Littman, D. R. & Mayer, L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957\u2013965 (2011).","journal-title":"Gastroenterology"},{"key":"2584_CR342","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3389\/fimmu.2019.02158","volume":"10","author":"M Di Giovangiulio","year":"2019","unstructured":"Di Giovangiulio, M. et al. Tbet expression in regulatory T cells is required to initiate Th1-mediated colitis. Front. Immunol. 10, 2158 (2019).","journal-title":"Front. Immunol."},{"key":"2584_CR343","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.gastro.2020.04.074","volume":"159","author":"V Mitsialis","year":"2020","unstructured":"Mitsialis, V. et al. Single-cell analyses of colon and blood reveal distinct immune cell signatures of ulcerative colitis and Crohn\u2019s disease. Gastroenterology 159, 591\u2013608.e510 (2020).","journal-title":"Gastroenterology"},{"key":"2584_CR344","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06413-6","volume":"23","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Treg and intestinal myofibroblasts-derived Amphiregulin induced by TGF-\u03b2 mediates intestinal fibrosis in Crohn\u2019s disease. J. Transl. Med. 23, 452 (2025).","journal-title":"J. Transl. Med."},{"key":"2584_CR345","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1826746","volume":"13","author":"L Fan","year":"2021","unstructured":"Fan, L. et al. B. adolescentis ameliorates chronic colitis by regulating Treg\/Th2 response and gut microbiota remodeling. Gut Microbes 13, 1\u201317 (2021).","journal-title":"Gut Microbes"},{"key":"2584_CR346","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45473-y","volume":"15","author":"L Jia","year":"2024","unstructured":"Jia, L. et al. Porphyromonas gingivalis aggravates colitis via a gut microbiota-linoleic acid metabolism-Th17\/Treg cell balance axis. Nat. Commun. 15, 1617 (2024).","journal-title":"Nat. Commun."},{"key":"2584_CR347","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.chom.2024.02.003","volume":"32","author":"S Carasso","year":"2024","unstructured":"Carasso, S. et al. Inflammation and bacteriophages affect DNA inversion states and functionality of the gut microbiota. Cell Host Microbe 32, 322\u2013334.e329 (2024).","journal-title":"Cell Host Microbe"},{"key":"2584_CR348","doi-asserted-by":"publisher","first-page":"114636","DOI":"10.1016\/j.celrep.2024.114636","volume":"43","author":"J Yan","year":"2024","unstructured":"Yan, J. et al. Inherent preference for polyunsaturated fatty acids instigates ferroptosis of Treg cells that aggravates high-fat-diet-related colitis. Cell Rep. 43, 114636 (2024).","journal-title":"Cell Rep."},{"key":"2584_CR349","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1042\/CS20230788","volume":"137","author":"M Zhou","year":"2023","unstructured":"Zhou, M. et al. High-fructose corn syrup aggravates colitis via microbiota dysbiosis-mediated Th17\/Treg imbalance. Clin. Sci. 137, 1619\u20131635 (2023).","journal-title":"Clin. Sci."},{"key":"2584_CR350","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38444-2","volume":"14","author":"L Zhu","year":"2023","unstructured":"Zhu, L. et al. Microbiota-assisted iron uptake promotes immune tolerance in the intestine. Nat. Commun. 14, 2790 (2023).","journal-title":"Nat. Commun."},{"key":"2584_CR351","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41590-021-00889-2","volume":"22","author":"J Quandt","year":"2021","unstructured":"Quandt, J. et al. Wnt-\u03b2-catenin activation epigenetically reprograms T(reg) cells in inflammatory bowel disease and dysplastic progression. Nat. Immunol. 22, 471\u2013484 (2021).","journal-title":"Nat. Immunol."},{"key":"2584_CR352","doi-asserted-by":"publisher","first-page":"112128","DOI":"10.1016\/j.celrep.2023.112128","volume":"42","author":"J Jacobse","year":"2023","unstructured":"Jacobse, J. et al. Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells. Cell Rep. 42, 112128 (2023).","journal-title":"Cell Rep."},{"key":"2584_CR353","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1053\/j.gastro.2024.01.026","volume":"166","author":"AO Bamidele","year":"2024","unstructured":"Bamidele, A. O. et al. Interleukin 21 drives a hypermetabolic state and CD4(+) T-Cell-associated pathogenicity in chronic intestinal inflammation. Gastroenterology 166, 826\u2013841.e819 (2024).","journal-title":"Gastroenterology"},{"key":"2584_CR354","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41590-025-02166-y","volume":"26","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch. Nat. Immunol. 26, 866\u2013880 (2025).","journal-title":"Nat. Immunol."},{"key":"2584_CR355","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41586-024-07251-0","volume":"628","author":"Y Gu","year":"2024","unstructured":"Gu, Y. et al. Immune microniches shape intestinal T(reg) function. Nature 628, 854\u2013862 (2024).","journal-title":"Nature"},{"key":"2584_CR356","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1126\/science.abi6087","volume":"374","author":"G Agirman","year":"2021","unstructured":"Agirman, G., Yu, K. B. & Hsiao, E. Y. Signaling inflammation across the gut-brain axis. Science 374, 1087\u20131092 (2021).","journal-title":"Science"},{"key":"2584_CR357","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1161\/CIRCRESAHA.125.325516","volume":"136","author":"M Snelson","year":"2025","unstructured":"Snelson, M. et al. Gut-heart axis: the role of gut microbiota and metabolites in heart failure. Circ. Res. 136, 1382\u20131406 (2025).","journal-title":"Circ. Res."},{"key":"2584_CR358","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.270","volume":"4","author":"X Lin","year":"2025","unstructured":"Lin, X. et al. Gut-X axis. iMeta 4, e270 (2025).","journal-title":"iMeta"},{"key":"2584_CR359","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi, A., Igel, T., Mok, C. C. & Arnaud, L. Systemic lupus erythematosus. Lancet 403, 2326\u20132338 (2024).","journal-title":"Lancet"},{"key":"2584_CR360","doi-asserted-by":"publisher","first-page":"102870","DOI":"10.1016\/j.jaut.2022.102870","volume":"132","author":"H Li","year":"2022","unstructured":"Li, H., Boulougoura, A., Endo, Y. & Tsokos, G. C. Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. J. Autoimmun. 132, 102870 (2022).","journal-title":"J. Autoimmun."},{"key":"2584_CR361","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.7150\/thno.63743","volume":"11","author":"HC Chuang","year":"2021","unstructured":"Chuang, H. C. et al. BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus. Theranostics 11, 9953\u20139966 (2021).","journal-title":"Theranostics"},{"key":"2584_CR362","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10020-023-00643-4","volume":"29","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. m(6)A methyltransferase METTL3 programs CD4(+) T-cell activation and effector T-cell differentiation in systemic lupus erythematosus. Mol. Med. 29, 46 (2023).","journal-title":"Mol. Med."},{"key":"2584_CR363","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451298","volume":"55","author":"H Guo","year":"2025","unstructured":"Guo, H. et al. Neutrophil extracellular traps participate in the pathogenesis of lupus through S100A10-mediated regulatory T-cell differentiation and functional abnormalities. Eur. J. Immunol. 55, e202451298 (2025).","journal-title":"Eur. J. Immunol."},{"key":"2584_CR364","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molimm.2024.05.003","volume":"171","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. IFN-\u03b1 affects Th17\/Treg cell balance through c-Maf and associated with the progression of EBV- SLE. Mol. Immunol. 171, 22\u201335 (2024).","journal-title":"Mol. Immunol."},{"key":"2584_CR365","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122167","volume":"3","author":"C Jacquemin","year":"2018","unstructured":"Jacquemin, C. et al. OX40L\/OX40 axis impairs follicular and natural Treg function in human SLE. JCI Insight 3, e122167 (2018).","journal-title":"JCI Insight"},{"key":"2584_CR366","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi4994","volume":"13","author":"M Scherlinger","year":"2021","unstructured":"Scherlinger, M. et al. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Sci. Transl. Med. 13, eabi4994 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR367","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.4049\/jimmunol.166.6.4216","volume":"166","author":"EE Solomou","year":"2001","unstructured":"Solomou, E. E. et al. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166, 4216\u20134222 (2001).","journal-title":"J. Immunol."},{"key":"2584_CR368","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1172\/JCI22854","volume":"115","author":"YT Juang","year":"2005","unstructured":"Juang, Y. T. et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Investig. 115, 996\u20131005 (2005).","journal-title":"J. Clin. Investig."},{"key":"2584_CR369","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/art.40380","volume":"70","author":"H Kato","year":"2018","unstructured":"Kato, H. & Perl, A. Blockade of treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus. Arthritis Rheumatol. 70, 427\u2013438 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"2584_CR370","doi-asserted-by":"publisher","first-page":"113013","DOI":"10.1016\/j.intimp.2024.113013","volume":"141","author":"J Yu","year":"2024","unstructured":"Yu, J. et al. Inflammatory factor-mediated miR-155\/SOCS1 signaling axis leads to Treg impairment in systemic lupus erythematosus. Int Immunopharmacol. 141, 113013 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2584_CR371","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc9657","volume":"8","author":"M Scherlinger","year":"2022","unstructured":"Scherlinger, M. et al. Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity. Sci. Adv. 8, eadc9657 (2022).","journal-title":"Sci. Adv."},{"key":"2584_CR372","doi-asserted-by":"publisher","first-page":"2363937","DOI":"10.1080\/07853890.2024.2363937","volume":"56","author":"S Du","year":"2024","unstructured":"Du, S. et al. FOXP3 gene polymorphisms increase the risk of systemic lupus erythematosus in a Han Chinese population. Ann. Med. 56, 2363937 (2024).","journal-title":"Ann. Med."},{"key":"2584_CR373","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","volume":"25","author":"GC Tsokos","year":"2024","unstructured":"Tsokos, G. C. The immunology of systemic lupus erythematosus. Nat. Immunol. 25, 1332\u20131343 (2024).","journal-title":"Nat. Immunol."},{"key":"2584_CR374","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"2584_CR375","doi-asserted-by":"publisher","first-page":"626193","DOI":"10.3389\/fimmu.2021.626193","volume":"12","author":"Q Jiang","year":"2021","unstructured":"Jiang, Q. et al. Function and role of regulatory T cells in rheumatoid arthritis. Front. Immunol. 12, 626193 (2021).","journal-title":"Front. Immunol."},{"key":"2584_CR376","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.cell.2021.03.056","volume":"184","author":"M Ota","year":"2021","unstructured":"Ota, M. et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell 184, 3006\u20133021.e3017 (2021).","journal-title":"Cell"},{"key":"2584_CR377","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45213-2","volume":"15","author":"KF Baker","year":"2024","unstructured":"Baker, K. F. et al. Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remission. Nat. Commun. 15, 1063 (2024).","journal-title":"Nat. Commun."},{"key":"2584_CR378","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrrheum.2016.69","volume":"12","author":"U Fearon","year":"2016","unstructured":"Fearon, U., Canavan, M., Biniecka, M. & Veale, D. J. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat. Rev. Rheumatol. 12, 385\u2013397 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2584_CR379","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm.3432","volume":"20","author":"N Komatsu","year":"2014","unstructured":"Komatsu, N. et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20, 62\u201368 (2014).","journal-title":"Nat. Med."},{"key":"2584_CR380","doi-asserted-by":"publisher","first-page":"103590","DOI":"10.1016\/j.redox.2025.103590","volume":"82","author":"H Satooka","year":"2025","unstructured":"Satooka, H., Nakamura, Y. & Hirata, T. ROS-dependent SOCS3 upregulation disrupts regulatory T cell stability during autoimmune disease development. Redox Biol. 82, 103590 (2025).","journal-title":"Redox Biol."},{"key":"2584_CR381","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141008","volume":"131","author":"A Levescot","year":"2021","unstructured":"Levescot, A. et al. IL-1\u03b2-driven osteoclastogenic Tregs accelerate bone erosion in arthritis. J. Clin. Investig. 131, e141008 (2021).","journal-title":"J. Clin. Investig."},{"key":"2584_CR382","doi-asserted-by":"publisher","first-page":"103333","DOI":"10.1016\/j.jaut.2024.103333","volume":"149","author":"K Hattori","year":"2024","unstructured":"Hattori, K. et al. Synovial regulatory T cells expressing ST2 deteriorate joint inflammation through the suppression of immunoregulatory eosinophils. J. Autoimmun. 149, 103333 (2024).","journal-title":"J. Autoimmun."},{"key":"2584_CR383","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.jaut.2021.102726","volume":"124","author":"A Meyer","year":"2021","unstructured":"Meyer, A. et al. Kinase activity profiling reveals contribution of G-protein signaling modulator 2 deficiency to impaired regulatory T cell migration in rheumatoid arthritis. J. Autoimmun. 124, 102726 (2021).","journal-title":"J. Autoimmun."},{"key":"2584_CR384","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00018-021-04076-2","volume":"79","author":"S Yan","year":"2021","unstructured":"Yan, S. et al. Membrane-bound IL-6R is upregulated on Th17 cells and inhibits Treg cell migration by regulating post-translational modification of VASP in autoimmune arthritis. Cell Mol. Life Sci. 79, 3 (2021).","journal-title":"Cell Mol. Life Sci."},{"key":"2584_CR385","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaut.2019.02.001","volume":"99","author":"I Cammarata","year":"2019","unstructured":"Cammarata, I. et al. Counter-regulation of regulatory T cells by autoreactive CD8(+) T cells in rheumatoid arthritis. J. Autoimmun. 99, 81\u201397 (2019).","journal-title":"J. Autoimmun."},{"key":"2584_CR386","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","volume":"15","author":"J Ilonen","year":"2019","unstructured":"Ilonen, J., Lempainen, J. & Veijola, R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol. 15, 635\u2013650 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2584_CR387","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.autrev.2020.102526","volume":"19","author":"JH Park","year":"2020","unstructured":"Park, J. H. et al. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: a systematic review. Autoimmun. Rev. 19, 102526 (2020).","journal-title":"Autoimmun. Rev."},{"key":"2584_CR388","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.4049\/jimmunol.1003099","volume":"186","author":"SA McClymont","year":"2011","unstructured":"McClymont, S. A. et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918\u20133926 (2011).","journal-title":"J. Immunol."},{"key":"2584_CR389","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13587-3","volume":"10","author":"MG Scherm","year":"2019","unstructured":"Scherm, M. G. et al. miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. Nat. Commun. 10, 5697 (2019).","journal-title":"Nat. Commun."},{"key":"2584_CR390","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.4049\/jimmunol.1001860","volume":"185","author":"AK Marwaha","year":"2010","unstructured":"Marwaha, A. K. et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 185, 3814\u20133818 (2010).","journal-title":"J. Immunol."},{"key":"2584_CR391","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123879","volume":"4","author":"AM Pesenacker","year":"2019","unstructured":"Pesenacker, A. M. et al. Treg gene signatures predict and measure type 1 diabetes trajectory. JCI Insight 4, e123879 (2019).","journal-title":"JCI Insight"},{"key":"2584_CR392","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.1073\/pnas.1815336116","volume":"116","author":"P Gao","year":"2019","unstructured":"Gao, P. et al. Risk variants disrupting enhancers of T(H)1 and T(REG) cells in type 1 diabetes. Proc. Natl. Acad. Sci. USA 116, 7581\u20137590 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR393","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ng2068","volume":"39","author":"JA Todd","year":"2007","unstructured":"Todd, J. A. et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39, 857\u2013864 (2007).","journal-title":"Nat. Genet."},{"key":"2584_CR394","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11892-020-01325-9","volume":"20","author":"MG Scherm","year":"2020","unstructured":"Scherm, M. G. & Daniel, C. miRNA regulation of T cells in islet autoimmunity and Type 1 diabetes. Curr. Diab Rep. 20, 41 (2020).","journal-title":"Curr. Diab Rep."},{"key":"2584_CR395","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1782","volume":"10","author":"I Serr","year":"2018","unstructured":"Serr, I. et al. A miRNA181a\/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes. Sci. Transl. Med. 10, eaag1782 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR396","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/db07-1499","volume":"57","author":"J Han","year":"2008","unstructured":"Han, J. et al. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 57, 2118\u20132127 (2008).","journal-title":"Diabetes"},{"key":"2584_CR397","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00125-020-05105-8","volume":"63","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability. Diabetologia 63, 987\u20131001 (2020).","journal-title":"Diabetologia"},{"key":"2584_CR398","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4049\/jimmunol.2300216","volume":"213","author":"S Grebinoski","year":"2024","unstructured":"Grebinoski, S. et al. Regulatory T cell insufficiency in autoimmune diabetes is driven by selective loss of neuropilin-1 on intraislet regulatory T cells. J. Immunol. 213, 779\u2013794 (2024).","journal-title":"J. Immunol."},{"key":"2584_CR399","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2337\/db09-0694","volume":"59","author":"SA Long","year":"2010","unstructured":"Long, S. A. et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 59, 407\u2013415 (2010).","journal-title":"Diabetes"},{"key":"2584_CR400","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","volume":"28","author":"Q Tang","year":"2008","unstructured":"Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687\u2013697 (2008).","journal-title":"Immunity"},{"key":"2584_CR401","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00592-025-02478-3","volume":"62","author":"AS Syed Khaja","year":"2025","unstructured":"Syed Khaja, A. S. et al. Dysregulation and therapeutic prospects of regulatory T cells in type 1 diabetes. Acta Diabetol. 62, 785\u2013800 (2025).","journal-title":"Acta Diabetol."},{"key":"2584_CR402","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ccell.2021.03.001","volume":"39","author":"M Villa","year":"2021","unstructured":"Villa, M., O\u2019Sullivan, D. & Pearce, E. L. Glucose makes T(reg) lose their temper. Cancer Cell 39, 460\u2013462 (2021).","journal-title":"Cancer Cell"},{"key":"2584_CR403","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147474","volume":"6","author":"S Dong","year":"2021","unstructured":"Dong, S. et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight 6, e147474 (2021).","journal-title":"JCI Insight"},{"key":"2584_CR404","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.2337\/db12-0049","volume":"61","author":"SA Long","year":"2012","unstructured":"Long, S. A. et al. Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs \u03b2-cell function. Diabetes 61, 2340\u20132348 (2012).","journal-title":"Diabetes"},{"key":"2584_CR405","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone, J. A. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7, 315ra189 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR406","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn2404","volume":"16","author":"C Bender","year":"2024","unstructured":"Bender, C. et al. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Sci. Transl. Med. 16, eadn2404 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR407","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby, P. The changing landscape of atherosclerosis. Nature 592, 524\u2013533 (2021).","journal-title":"Nature"},{"key":"2584_CR408","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319\u2013328 (2018).","journal-title":"Lancet"},{"key":"2584_CR409","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2584_CR410","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm1343","volume":"12","author":"H Ait-Oufella","year":"2006","unstructured":"Ait-Oufella, H. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12, 178\u2013180 (2006).","journal-title":"Nat. Med."},{"key":"2584_CR411","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1172\/JCI63891","volume":"123","author":"R Klingenberg","year":"2013","unstructured":"Klingenberg, R. et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J. Clin. Investig. 123, 1323\u20131334 (2013).","journal-title":"J. Clin. Investig."},{"key":"2584_CR412","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/01.ATV.0000259365.31469.89","volume":"27","author":"A Mor","year":"2007","unstructured":"Mor, A. et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb. Vasc. Biol. 27, 893\u2013900 (2007).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"2584_CR413","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.119.316461","volume":"127","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ. Res. 127, 335\u2013353 (2020).","journal-title":"Circ. Res."},{"key":"2584_CR414","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.immuni.2018.07.015","volume":"49","author":"JD Proto","year":"2018","unstructured":"Proto, J. D. et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity 49, 666\u2013677.e666 (2018).","journal-title":"Immunity"},{"key":"2584_CR415","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1161\/CIRCRESAHA.117.312340","volume":"122","author":"AL Joly","year":"2018","unstructured":"Joly, A. L. et al. Alternative splicing of FOXP3 controls regulatory T cell effector functions and is associated with human atherosclerotic plaque stability. Circ. Res. 122, 1385\u20131394 (2018).","journal-title":"Circ. Res."},{"key":"2584_CR416","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1161\/CIRCRESAHA.116.309764","volume":"119","author":"MJ Butcher","year":"2016","unstructured":"Butcher, M. J. et al. Atherosclerosis-driven treg plasticity results in formation of a dysfunctional subset of plastic IFN\u03b3+ Th1\/Tregs. Circ. Res. 119, 1190\u20131203 (2016).","journal-title":"Circ. Res."},{"key":"2584_CR417","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1161\/CIRCRESAHA.116.308648","volume":"118","author":"J Li","year":"2016","unstructured":"Li, J. et al. CCR5+T-bet+FoxP3+ effector CD4 T cells drive atherosclerosis. Circ. Res. 118, 1540\u20131552 (2016).","journal-title":"Circ. Res."},{"key":"2584_CR418","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03493-5","volume":"9","author":"DE Gaddis","year":"2018","unstructured":"Gaddis, D. E. et al. Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. Nat. Commun. 9, 1095 (2018).","journal-title":"Nat. Commun."},{"key":"2584_CR419","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s44161-023-00218-w","volume":"2","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis. Nat. Cardiovasc. Res. 2, 290\u2013306 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2584_CR420","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.117.031420","volume":"138","author":"T Kimura","year":"2018","unstructured":"Kimura, T. et al. Regulatory CD4(+) T cells recognize major histocompatibility complex class II molecule-restricted peptide epitopes of apolipoprotein B. Circulation 138, 1130\u20131143 (2018).","journal-title":"Circulation"},{"key":"2584_CR421","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s44161-022-00063-3","volume":"1","author":"R Saigusa","year":"2022","unstructured":"Saigusa, R. et al. Single cell transcriptomics and TCR reconstruction reveal CD4 T cell response to MHC-II-restricted APOB epitope in human cardiovascular disease. Nat. Cardiovasc Res. 1, 462\u2013475 (2022).","journal-title":"Nat. Cardiovasc Res."},{"key":"2584_CR422","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1161\/CIRCULATIONAHA.119.042863","volume":"142","author":"D Wolf","year":"2020","unstructured":"Wolf, D. et al. Pathogenic autoimmunity in atherosclerosis evolves from initially protective apolipoprotein B(100)-reactive CD4(+) T-regulatory cells. Circulation 142, 1279\u20131293 (2020).","journal-title":"Circulation"},{"key":"2584_CR423","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1093\/eurheartj\/ehl222","volume":"27","author":"A Mor","year":"2006","unstructured":"Mor, A. et al. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur. Heart J. 27, 2530\u20132537 (2006).","journal-title":"Eur. Heart J."},{"key":"2584_CR424","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138274","volume":"5","author":"W Li","year":"2020","unstructured":"Li, W. et al. T cells expressing the lupus susceptibility allele Pbx1d enhance autoimmunity and atherosclerosis in dyslipidemic mice. JCI Insight 5, e138274 (2020).","journal-title":"JCI Insight"},{"key":"2584_CR425","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1161\/HYPERTENSIONAHA.119.12852","volume":"74","author":"L Zhu","year":"2019","unstructured":"Zhu, L. et al. Elevated methylation of FOXP3 (forkhead Box P3)-TSDR (regulatory T-cell-specific demethylated region) is associated with increased risk for adverse outcomes in patients with acute coronary syndrome. Hypertension 74, 581\u2013589 (2019).","journal-title":"Hypertension"},{"key":"2584_CR426","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/CIRCRESAHA.121.318052","volume":"128","author":"MS Madhur","year":"2021","unstructured":"Madhur, M. S. et al. Hypertension: do inflammation and immunity hold the key to solving this epidemic? Circ. Res. 128, 908\u2013933 (2021).","journal-title":"Circ. Res."},{"key":"2584_CR427","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/HYPERTENSIONAHA.110.162941","volume":"57","author":"T Barhoumi","year":"2011","unstructured":"Barhoumi, T. et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57, 469\u2013476 (2011).","journal-title":"Hypertension"},{"key":"2584_CR428","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126155","volume":"132","author":"T Failer","year":"2022","unstructured":"Failer, T. et al. Developmental endothelial locus-1 protects from hypertension-induced cardiovascular remodeling via immunomodulation. J. Clin. Investig. 132, e126155 (2022).","journal-title":"J. Clin. Investig."},{"key":"2584_CR429","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1161\/CIRCULATIONAHA.119.045344","volume":"142","author":"C Cui","year":"2020","unstructured":"Cui, C. et al. CD4(+) T-cell endogenous cystathionine \u03b3 lyase-hydrogen sulfide attenuates hypertension by sulfhydrating liver kinase B1 to promote T regulatory cell differentiation and proliferation. Circulation 142, 1752\u20131769 (2020).","journal-title":"Circulation"},{"key":"2584_CR430","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009372","volume":"8","author":"MF Iulita","year":"2019","unstructured":"Iulita, M. F. et al. CD4(+) regulatory T lymphocytes prevent impaired cerebral blood flow in angiotensin ii-induced hypertension. J. Am. Heart Assoc. 8, e009372 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"2584_CR431","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/CIRCRESAHA.117.312153","volume":"122","author":"XH Chen","year":"2018","unstructured":"Chen, X. H. et al. Deficiency of complement C3a and C5a receptors prevents angiotensin II-induced hypertension via regulatory T cells. Circ. Res. 122, 970\u2013983 (2018).","journal-title":"Circ. Res."},{"key":"2584_CR432","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1161\/HYPERTENSIONAHA.123.20481","volume":"80","author":"X Sun","year":"2023","unstructured":"Sun, X. et al. Hypertension-driven regulatory T-cell perturbations accelerate myocardial ischemia-reperfusion injury. Hypertension 80, 2046\u20132058 (2023).","journal-title":"Hypertension"},{"key":"2584_CR433","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1161\/CIRCRESAHA.123.322835","volume":"134","author":"Y He","year":"2024","unstructured":"He, Y. et al. CD4+ T-cell legumain deficiency attenuates hypertensive damage via preservation of TRAF6. Circ. Res. 134, 9\u201329 (2024).","journal-title":"Circ. Res."},{"key":"2584_CR434","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.numecd.2019.08.004","volume":"29","author":"SK Hong","year":"2019","unstructured":"Hong, S. K., Choo, E. H., Ihm, S. H. & Chang, K. Y. High fat diet downregulates regulatory T cells in the myocardium of spontaneous hypertensive rats. Nutr. Metab. Cardiovasc Dis. 29, 1254\u20131260 (2019).","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"2584_CR435","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1161\/CIRCRESAHA.115.306883","volume":"118","author":"FB Ortega","year":"2016","unstructured":"Ortega, F. B., Lavie, C. J. & Blair, S. N. Obesity and cardiovascular disease. Circ. Res. 118, 1752\u20131770 (2016).","journal-title":"Circ. Res."},{"key":"2584_CR436","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1042\/CS20200895","volume":"135","author":"EB Taylor","year":"2021","unstructured":"Taylor, E. B. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin. Sci. 135, 731\u2013752 (2021).","journal-title":"Clin. Sci."},{"key":"2584_CR437","doi-asserted-by":"publisher","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","volume":"320","author":"T Kawai","year":"2021","unstructured":"Kawai, T., Autieri, M. V. & Scalia, R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am. J. Physiol. Cell Physiol. 320, C375\u2013c391 (2021).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2584_CR438","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","volume":"127","author":"AR Saltiel","year":"2017","unstructured":"Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Investig. 127, 1\u20134 (2017).","journal-title":"J. Clin. Investig."},{"key":"2584_CR439","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nature04634","volume":"440","author":"N Houstis","year":"2006","unstructured":"Houstis, N., Rosen, E. D. & Lander, E. S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944\u2013948 (2006).","journal-title":"Nature"},{"key":"2584_CR440","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nri2449","volume":"8","author":"GS Hotamisligil","year":"2008","unstructured":"Hotamisligil, G. S. & Erbay, E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 8, 923\u2013934 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR441","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.cell.2014.05.012","volume":"157","author":"YS Lee","year":"2014","unstructured":"Lee, Y. S. et al. Increased adipocyte O2 consumption triggers HIF-1\u03b1, causing inflammation and insulin resistance in obesity. Cell 157, 1339\u20131352 (2014).","journal-title":"Cell"},{"key":"2584_CR442","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature11132","volume":"486","author":"D Cipolletta","year":"2012","unstructured":"Cipolletta, D. et al. PPAR-\u03b3 is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549\u2013553 (2012).","journal-title":"Nature"},{"key":"2584_CR443","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cmet.2015.03.005","volume":"21","author":"D Kolodin","year":"2015","unstructured":"Kolodin, D. et al. Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab. 21, 543\u2013557 (2015).","journal-title":"Cell Metab."},{"key":"2584_CR444","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ni.3085","volume":"16","author":"A Vasanthakumar","year":"2015","unstructured":"Vasanthakumar, A. et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat. Immunol. 16, 276\u2013285 (2015).","journal-title":"Nat. Immunol."},{"key":"2584_CR445","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nm.2002","volume":"15","author":"M Feuerer","year":"2009","unstructured":"Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930\u2013939 (2009).","journal-title":"Nat. Med."},{"key":"2584_CR446","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cmet.2021.06.007","volume":"33","author":"C Li","year":"2021","unstructured":"Li, C. et al. Interferon-\u03b1-producing plasmacytoid dendritic cells drive the loss of adipose tissue regulatory T cells during obesity. Cell Metab. 33, 1610\u20131623.e1615 (2021).","journal-title":"Cell Metab."},{"key":"2584_CR447","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adl4909","volume":"10","author":"C Elkins","year":"2025","unstructured":"Elkins, C. et al. Obesity reshapes regulatory T cells in the visceral adipose tissue by disrupting cellular cholesterol homeostasis. Sci. Immunol. 10, eadl4909 (2025).","journal-title":"Sci. Immunol."},{"key":"2584_CR448","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2015.05.019","volume":"43","author":"AB Molofsky","year":"2015","unstructured":"Molofsky, A. B. et al. Interleukin-33 and interferon-\u03b3 counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 43, 161\u2013174 (2015).","journal-title":"Immunity"},{"key":"2584_CR449","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nature16151","volume":"528","author":"SP Bapat","year":"2015","unstructured":"Bapat, S. P. et al. Depletion of fat-resident Treg cells prevents age-associated insulin resistance. Nature 528, 137\u2013141 (2015).","journal-title":"Nature"},{"key":"2584_CR450","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140644","volume":"6","author":"LY Beppu","year":"2021","unstructured":"Beppu, L. Y. et al. Tregs facilitate obesity and insulin resistance via a Blimp-1\/IL-10 axis. JCI Insight 6, e140644 (2021).","journal-title":"JCI Insight"},{"key":"2584_CR451","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"2584_CR452","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2024.01.009","volume":"57","author":"TM Savage","year":"2024","unstructured":"Savage, T. M. et al. Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis. Immunity 57, 303\u2013318.e306 (2024).","journal-title":"Immunity"},{"key":"2584_CR453","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp7193","volume":"10","author":"K Wang","year":"2025","unstructured":"Wang, K. et al. ATF4 drives regulatory T cell functional specification in homeostasis and obesity. Sci. Immunol. 10, eadp7193 (2025).","journal-title":"Sci. Immunol."},{"key":"2584_CR454","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou, S. L. et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 150, 1646\u20131658.e1617 (2016).","journal-title":"Gastroenterology"},{"key":"2584_CR455","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl7209","volume":"7","author":"R Yamagishi","year":"2022","unstructured":"Yamagishi, R. et al. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma. Sci. Immunol. 7, eabl7209 (2022).","journal-title":"Sci. Immunol."},{"key":"2584_CR456","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175305","volume":"134","author":"D Aki","year":"2024","unstructured":"Aki, D. et al. The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models. J. Clin. Investig. 134, e175305 (2024).","journal-title":"J. Clin. Investig."},{"key":"2584_CR457","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/hep.21823","volume":"46","author":"X Ma","year":"2007","unstructured":"Ma, X. et al. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46, 1519\u20131529 (2007).","journal-title":"Hepatology"},{"key":"2584_CR458","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon, H. S. & Koh, S. H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl. Neurodegener. 9, 42 (2020).","journal-title":"Transl. Neurodegener."},{"key":"2584_CR459","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41577-023-00960-z","volume":"24","author":"A Liston","year":"2024","unstructured":"Liston, A., Pasciuto, E., Fitzgerald, D. C. & Yshii, L. Brain regulatory T cells. Nat. Rev. Immunol. 24, 326\u2013337 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR460","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02702-3","volume":"20","author":"G Stym-Popper","year":"2023","unstructured":"Stym-Popper, G. et al. Regulatory T cells decrease C3-positive reactive astrocytes in Alzheimer-like pathology. J. Neuroinflammation 20, 64 (2023).","journal-title":"J. Neuroinflammation"},{"key":"2584_CR461","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02512-z","volume":"19","author":"SY Park","year":"2022","unstructured":"Park, S. Y. et al. Neuroprotective effects of ex vivo-expanded regulatory T cells on trimethyltin-induced neurodegeneration in mice. J. Neuroinflammation 19, 143 (2022).","journal-title":"J. Neuroinflammation"},{"key":"2584_CR462","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8967","volume":"6","author":"K Baruch","year":"2015","unstructured":"Baruch, K. et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer\u2019s disease pathology. Nat. Commun. 6, 7967 (2015).","journal-title":"Nat. Commun."},{"key":"2584_CR463","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89530","volume":"2","author":"DR Beers","year":"2017","unstructured":"Beers, D. R. et al. ALS patients\u2019 regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2, e89530 (2017).","journal-title":"JCI Insight"},{"key":"2584_CR464","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45742-w","volume":"15","author":"AG de la Fuente","year":"2024","unstructured":"de la Fuente, A. G. et al. Ageing impairs the regenerative capacity of regulatory T cells in mouse central nervous system remyelination. Nat. Commun. 15, 1870 (2024).","journal-title":"Nat. Commun."},{"key":"2584_CR465","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","volume":"16","author":"BN Lambrecht","year":"2015","unstructured":"Lambrecht, B. N. & Hammad, H. The immunology of asthma. Nat. Immunol. 16, 45\u201356 (2015).","journal-title":"Nat. Immunol."},{"key":"2584_CR466","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/ni1122","volume":"5","author":"P Stock","year":"2004","unstructured":"Stock, P. et al. Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat. Immunol. 5, 1149\u20131156 (2004).","journal-title":"Nat. Immunol."},{"key":"2584_CR467","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/nm745","volume":"8","author":"O Akbari","year":"2002","unstructured":"Akbari, O. et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8, 1024\u20131032 (2002).","journal-title":"Nat. Med."},{"key":"2584_CR468","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/all.16551","volume":"80","author":"S Choi","year":"2025","unstructured":"Choi, S. et al. Asthma alleviation by ginsenoside Rb1 via promotion of treg proliferation and inflammatory T cell inhibition. Allergy 80, 1647\u20131668 (2025).","journal-title":"Allergy"},{"key":"2584_CR469","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165689","volume":"134","author":"H Li","year":"2024","unstructured":"Li, H. et al. TXA2 attenuates allergic lung inflammation through regulation of Th2, Th9, and Treg differentiation. J. Clin. Investig. 134, e165689 (2024).","journal-title":"J. Clin. Investig."},{"key":"2584_CR470","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41590-020-0777-3","volume":"21","author":"H Harb","year":"2020","unstructured":"Harb, H. et al. A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma. Nat. Immunol. 21, 1359\u20131370 (2020).","journal-title":"Nat. Immunol."},{"key":"2584_CR471","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2020.03.002","volume":"146","author":"B Koh","year":"2020","unstructured":"Koh, B. et al. Bcl6 and Blimp1 reciprocally regulate ST2(+) Treg-cell development in the context of allergic airway inflammation. J. Allergy Clin. Immunol. 146, 1121\u20131136.e1129 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2584_CR472","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jaci.2017.01.015","volume":"140","author":"CC Chen","year":"2017","unstructured":"Chen, C. C. et al. IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs. J. Allergy Clin. Immunol. 140, 1351\u20131363.e1357 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2584_CR473","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153397","volume":"132","author":"VD Gandhi","year":"2022","unstructured":"Gandhi, V. D. et al. Androgen receptor signaling promotes Treg suppressive function during allergic airway inflammation. J. Clin. Investig. 132, e153397 (2022).","journal-title":"J. Clin. Investig."},{"key":"2584_CR474","doi-asserted-by":"publisher","first-page":"2301752","DOI":"10.1183\/13993003.01752-2023","volume":"64","author":"A Aili","year":"2024","unstructured":"Aili, A. et al. LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells. Eur. Respir. J. 64, 2301752 (2024).","journal-title":"Eur. Respir. J."},{"key":"2584_CR475","doi-asserted-by":"publisher","first-page":"103594","DOI":"10.1016\/j.redox.2025.103594","volume":"82","author":"P Tao","year":"2025","unstructured":"Tao, P. et al. Interleukin-35 inhibits NETs to ameliorate Th17\/Treg immune imbalance during the exacerbation of cigarette smoke exposed-asthma via gp130\/STAT3\/ferroptosis axis. Redox Biol. 82, 103594 (2025).","journal-title":"Redox Biol."},{"key":"2584_CR476","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaci.2010.08.008","volume":"126","author":"K Nadeau","year":"2010","unstructured":"Nadeau, K. et al. Ambient air pollution impairs regulatory T-cell function in asthma. J. Allergy Clin. Immunol. 126, 845\u2013852.e810 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2584_CR477","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaci.2019.10.008","volume":"145","author":"L Sun","year":"2020","unstructured":"Sun, L. et al. Particulate matter of 2.5 \u03bcm or less in diameter disturbs the balance of T(H)17\/regulatory T cells by targeting glutamate oxaloacetate transaminase 1 and hypoxia-inducible factor 1\u03b1 in an asthma model. J. Allergy Clin. Immunol. 145, 402\u2013414 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2584_CR478","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.it.2023.04.005","volume":"44","author":"S Bittner","year":"2023","unstructured":"Bittner, S., Hehlgans, T. & Feuerer, M. Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond. Trends Immunol. 44, 468\u2013483 (2023).","journal-title":"Trends Immunol."},{"key":"2584_CR479","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cmet.2023.12.019","volume":"36","author":"M Becker","year":"2024","unstructured":"Becker, M. et al. Niche-specific control of tissue function by regulatory T cells-current challenges and perspectives for targeting metabolic disease. Cell Metab. 36, 229\u2013239 (2024).","journal-title":"Cell Metab."},{"key":"2584_CR480","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi, S. et al. Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541\u2013566 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"2584_CR481","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648\u2013659 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2584_CR482","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich, J. Y. et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann. Rheum. Dis. 81, 1685\u20131694 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2584_CR483","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003500","volume":"10","author":"F Barde","year":"2024","unstructured":"Barde, F. et al. Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study. RMD Open 10, e003500 (2024).","journal-title":"RMD Open"},{"key":"2584_CR484","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba5264","volume":"5","author":"L Khoryati","year":"2020","unstructured":"Khoryati, L. et al. An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice. Sci. Immunol. 5, eaba5264 (2020).","journal-title":"Sci. Immunol."},{"key":"2584_CR485","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","volume":"5","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat. Biomed. Eng. 5, 1288\u20131305 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"2584_CR486","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/imr.12845","volume":"295","author":"H Huang","year":"2020","unstructured":"Huang, H. et al. mTOR signaling at the crossroads of environmental signals and T-cell fate decisions. Immunol. Rev. 295, 15\u201338 (2020).","journal-title":"Immunol. Rev."},{"key":"2584_CR487","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1084\/jem.20071477","volume":"205","author":"S Haxhinasto","year":"2008","unstructured":"Haxhinasto, S., Mathis, D. & Benoist, C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565\u2013574 (2008).","journal-title":"J. Exp. Med."},{"key":"2584_CR488","first-page":"58","volume":"38","author":"HQ Niu","year":"2020","unstructured":"Niu, H. Q. et al. Sirolimus selectively increases circulating Treg cell numbers and restores the Th17\/Treg balance in rheumatoid arthritis patients with low disease activity or in DAS28 remission who previously received conventional disease-modifying anti-rheumatic drugs. Clin. Exp. Rheumatol. 38, 58\u201366 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2584_CR489","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40734-8","volume":"14","author":"J Mandrioli","year":"2023","unstructured":"Mandrioli, J. et al. Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis. Nat. Commun. 14, 4970 (2023).","journal-title":"Nat. Commun."},{"key":"2584_CR490","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/TP.0000000000002495","volume":"103","author":"R Gedaly","year":"2019","unstructured":"Gedaly, R. et al. mTOR inhibitor everolimus in regulatory T cell expansion for clinical application in transplantation. Transplantation 103, 705\u2013715 (2019).","journal-title":"Transplantation"},{"key":"2584_CR491","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13075-017-1357-2","volume":"19","author":"BR Oh","year":"2017","unstructured":"Oh, B. R. et al. Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro. Arthritis Res. Ther. 19, 154 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"2584_CR492","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/crj.12227","volume":"10","author":"X Hou","year":"2016","unstructured":"Hou, X. et al. Histone deacetylase inhibitor regulates the balance of Th17\/Treg in allergic asthma. Clin. Respir. J. 10, 371\u2013379 (2016).","journal-title":"Clin. Respir. J."},{"key":"2584_CR493","doi-asserted-by":"publisher","first-page":"21666","DOI":"10.1073\/pnas.1909687116","volume":"116","author":"WY Tseng","year":"2019","unstructured":"Tseng, W. Y. et al. TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells. Proc. Natl. Acad. Sci. USA 116, 21666\u201321672 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2584_CR494","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1084\/jem.20151255","volume":"213","author":"DX Nguyen","year":"2016","unstructured":"Nguyen, D. X. & Ehrenstein, M. R. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J. Exp. Med. 213, 1241\u20131253 (2016).","journal-title":"J. Exp. Med."},{"key":"2584_CR495","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.43","volume":"5","author":"Y Okubo","year":"2016","unstructured":"Okubo, Y. et al. Treg activation defect in type 1 diabetes: correction with TNFR2 agonism. Clin. Transl. Immunol. 5, e56 (2016).","journal-title":"Clin. Transl. Immunol."},{"key":"2584_CR496","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02785-y","volume":"20","author":"V Pegoretti","year":"2023","unstructured":"Pegoretti, V. et al. Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS. J. Neuroinflammation 20, 106 (2023).","journal-title":"J. Neuroinflammation"},{"key":"2584_CR497","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1053\/j.gastro.2019.01.025","volume":"156","author":"R Goldberg","year":"2019","unstructured":"Goldberg, R. et al. Correction of defective T-regulatory cells from patients with Crohn\u2019s disease by ex vivo ligation of retinoic acid receptor-\u03b1. Gastroenterology 156, 1775\u20131787 (2019).","journal-title":"Gastroenterology"},{"key":"2584_CR498","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200019","volume":"9","author":"JR Thonhoff","year":"2022","unstructured":"Thonhoff, J. R. et al. Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflammation 9, e200019 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"2584_CR499","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13024-023-00692-7","volume":"18","author":"P Yeapuri","year":"2023","unstructured":"Yeapuri, P. et al. Amyloid-\u03b2 specific regulatory T cells attenuate Alzheimer\u2019s disease pathobiology in APP\/PS1 mice. Mol. Neurodegener. 18, 97 (2023).","journal-title":"Mol. Neurodegener."},{"key":"2584_CR500","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1716","volume":"14","author":"SJ Yang","year":"2022","unstructured":"Yang, S. J. et al. Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models. Sci. Transl. Med. 14, eabn1716 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR501","doi-asserted-by":"publisher","first-page":"102401","DOI":"10.1016\/j.jaut.2020.102401","volume":"108","author":"M Malviya","year":"2020","unstructured":"Malviya, M. et al. Treatment of experimental autoimmune encephalomyelitis with engineered bi-specific Foxp3+ regulatory CD4+ T cells. J. Autoimmun. 108, 102401 (2020).","journal-title":"J. Autoimmun."},{"key":"2584_CR502","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar4567","volume":"16","author":"H Asnagli","year":"2014","unstructured":"Asnagli, H. et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Res. Ther. 16, R115 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"2584_CR503","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw4744","volume":"12","author":"SK Eskandari","year":"2020","unstructured":"Eskandari, S. K. et al. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter. Sci. Transl. Med. 12, eaaw4744 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR504","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41592-021-01201-8","volume":"18","author":"JA Pai","year":"2021","unstructured":"Pai, J. A. & Satpathy, A. T. High-throughput and single-cell T cell receptor sequencing technologies. Nat. Methods 18, 881\u2013892 (2021).","journal-title":"Nat. Methods"},{"key":"2584_CR505","doi-asserted-by":"publisher","first-page":"107411","DOI":"10.1016\/j.biotechadv.2019.06.010","volume":"37","author":"TI Panagopoulou","year":"2019","unstructured":"Panagopoulou, T. I. & Rafiq, Q. A. CAR-T immunotherapies: biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. Biotechnol. Adv. 37, 107411 (2019).","journal-title":"Biotechnol. Adv."},{"key":"2584_CR506","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat. Commun. 15, 2542 (2024).","journal-title":"Nat. Commun."},{"key":"2584_CR507","volume":"133","author":"JA Spanier","year":"2023","unstructured":"Spanier, J. A. et al. Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice. J. Clin. Investig. 133, e168601 (2023).","journal-title":"J. Clin. Investig."},{"key":"2584_CR508","doi-asserted-by":"publisher","first-page":"jjae135","DOI":"10.1093\/ecco-jcc\/jjae135","volume":"19","author":"Y Cui","year":"2024","unstructured":"Cui, Y. et al. IL23R-specific CAR Tregs for the treatment of Crohn\u2019s disease. J. Crohns Colitis 19, jjae135 (2024).","journal-title":"J. Crohns Colitis"},{"key":"2584_CR509","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.jaut.2022.102961","volume":"134","author":"DA Boardman","year":"2023","unstructured":"Boardman, D. A. et al. Flagellin-specific human CAR Tregs for immune regulation in IBD. J. Autoimmun. 134, 102961 (2023).","journal-title":"J. Autoimmun."},{"key":"2584_CR510","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","volume":"8","author":"J Skuljec","year":"2017","unstructured":"Skuljec, J. et al. Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma. Front. Immunol. 8, 1125 (2017).","journal-title":"Front. Immunol."},{"key":"2584_CR511","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz3866","volume":"12","author":"NAJ Dawson","year":"2020","unstructured":"Dawson, N. A. J. et al. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Sci. Transl. Med. 12, eaaz3866 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2584_CR512","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26844-1","volume":"12","author":"B Lamarth\u00e9e","year":"2021","unstructured":"Lamarth\u00e9e, B. et al. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction. Nat. Commun. 12, 6446 (2021).","journal-title":"Nat. Commun."},{"key":"2584_CR513","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert, M. L. et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann. Oncol. 32, 34\u201348 (2021).","journal-title":"Ann. Oncol."},{"key":"2584_CR514","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2019.03.053","volume":"453","author":"T Higuchi","year":"2019","unstructured":"Higuchi, T. et al. Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells. Cancer Lett. 453, 184\u2013192 (2019).","journal-title":"Cancer Lett."},{"key":"2584_CR515","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13826-7","volume":"11","author":"M Scortegagna","year":"2020","unstructured":"Scortegagna, M. et al. Siah2 control of T-regulatory cells limits anti-tumor immunity. Nat. Commun. 11, 99 (2020).","journal-title":"Nat. Commun."},{"key":"2584_CR516","doi-asserted-by":"publisher","first-page":"740588","DOI":"10.3389\/fimmu.2022.740588","volume":"13","author":"T Sarkar","year":"2022","unstructured":"Sarkar, T. et al. FOXP3\/HAT1 axis controls treg infiltration in the tumor microenvironment by inducing CCR4 expression in breast cancer. Front. Immunol. 13, 740588 (2022).","journal-title":"Front. Immunol."},{"key":"2584_CR517","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","volume":"76","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J. Hepatol. 76, 148\u2013159 (2022).","journal-title":"J. Hepatol."},{"key":"2584_CR518","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1158\/0008-5472.CAN-16-0618","volume":"76","author":"J Klarquist","year":"2016","unstructured":"Klarquist, J. et al. Ccl22 diverts T regulatory cells and controls the growth of melanoma. Cancer Res. 76, 6230\u20136240 (2016).","journal-title":"Cancer Res."},{"key":"2584_CR519","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005151","volume":"10","author":"H Ni","year":"2022","unstructured":"Ni, H. et al. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer. J. Immunother. Cancer 10, e005151 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2584_CR520","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1158\/0008-5472.CAN-18-3604","volume":"79","author":"F Li","year":"2019","unstructured":"Li, F. et al. Retinoblastoma inactivation induces a protumoral microenvironment via enhanced CCL2 secretion. Cancer Res. 79, 3903\u20133915 (2019).","journal-title":"Cancer Res."},{"key":"2584_CR521","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi5781","volume":"7","author":"BL Cadilha","year":"2021","unstructured":"Cadilha, B. L. et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci. Adv. 7, eabi5781 (2021).","journal-title":"Sci. Adv."},{"key":"2584_CR522","doi-asserted-by":"publisher","first-page":"619932","DOI":"10.3389\/fimmu.2021.619932","volume":"12","author":"Z Hui","year":"2021","unstructured":"Hui, Z. et al. Single-cell sequencing reveals the transcriptome and TCR characteristics of pTregs and in vitro expanded iTregs. Front. Immunol. 12, 619932 (2021).","journal-title":"Front. Immunol."},{"key":"2584_CR523","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41368-023-00267-8","volume":"16","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma. Int. J. Oral. Sci. 16, 9 (2024).","journal-title":"Int. J. Oral. Sci."},{"key":"2584_CR524","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41416-024-02702-x","volume":"130","author":"S Santagata","year":"2024","unstructured":"Santagata, S. et al. Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients. Br. J. Cancer 130, 2016\u20132026 (2024).","journal-title":"Br. J. Cancer"},{"key":"2584_CR525","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1172\/JCI90499","volume":"127","author":"NA Taylor","year":"2017","unstructured":"Taylor, N. A. et al. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J. Clin. Investig. 127, 3472\u20133483 (2017).","journal-title":"J. Clin. Investig."},{"key":"2584_CR526","doi-asserted-by":"publisher","first-page":"10170","DOI":"10.1158\/0008-5472.CAN-10-1943","volume":"70","author":"C D\u00fcrr","year":"2010","unstructured":"D\u00fcrr, C. et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 70, 10170\u201310181 (2010).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02584-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02584-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02584-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:03:46Z","timestamp":1780311826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02584-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":526,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2584"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02584-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"23 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}